About this Author
Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases.
To contact Derek email him directly: derekb.lowe@gmail.com
Twitter: Dereklowe
|
Date Index
May 2012
23:
How Come?
23:
Drug Discovery on Radio 4
23:
Another Vote Against Rhodanines
22:
The NIH's Drug Repurposing Initiative: Will It Be a Waste?
22:
The Counting of Beans
21:
A New Way to Kill Amoebas, From An Old Drug
21:
A Molecular Craigslist?
18:
The Genetic Diversity of Cancer Cells
18:
Strangely Good Results in Diabetes and Cardiovascular Disease
17:
Is HDL Always "Good Cholesterol"?
17:
The Breslow Chirality Paper Mess, Resolved
17:
A Preventative Trial for Alzheimer's: The Right Experiment
16:
Antidepressant Drugs and Cell Membranes
15:
Things I Won't Work With: Selenophenol
14:
Bosutinib: Don't Believe the Label!
14:
Do Industrial Post-Doc Positions Work?
11:
Desperation In the Lab
11:
Competitive Intelligence: Too Much or Too Little?
10:
The World of Metal-Catalyzed Couplings
10:
Arena and Lorcaserin, Back at the FDA
10:
The UK Goes Open-Access
10:
GSK Goes Hostile
09:
One More on That Buckyball Longevity Paper
09:
More Reaction Discovery (Now With Antibody Detection)
09:
PhDs On Food Stamps?
08:
Laboratory Crime, Not Paying
08:
Buckyball Longevity: The Lead Author Replies
07:
More Details
07:
You're A Peer, Too, You Know
07:
The CETP Saga Continues (And It's Not Getting More Entertaining)
04:
Cytotoxic? You Bet!
04:
Benlysta's Adventures In the Real World
04:
GSK with AstraZeneca?
03:
The Biotech Class of the Early 90s
03:
A Long-Delayed COX2 Issue Gets Settled - For $450 Million?
02:
Resveratrol Explained. A Little Bit.
01:
Flip That Glucose, Please
01:
Chemists and Biologists, In Detail
01:
Regulatory Hurdles
April 2012
30:
India's First Drug Isn't India's First Drug
30:
AstraZeneca Shuffles the Top Cards
27:
How Do Drugs Get Into Cells? A Vicious Debate.
27:
Different Worlds: A Last DHFR Paper Thought
26:
Elsevier Picks Up the Pace
25:
DHFR Inhibitors Revisited: A Word From the Authors (and Reviewers)
25:
Breslow's Chirality Paper: More Than Just Alien Dinosaurs
25:
Drug Company Culture: It's Not Helping
25:
Merck Serono Cuts Back
24:
That's Some Fine Editorial Work There
24:
AstraZeneca Buys Ardea. And Who Else?
24:
Harvard's Had Enough
23:
Making Their Own ALS Drug
20:
Buckyball Longevity - There's A Problem
18:
Buckyballs Prolong Life? Really?
18:
Build Your Own Reactive Reactors
18:
How Do These Things Get Published?
17:
Day Off
16:
Phenotypic Screening's Comeback
13:
More on the Federation of Independent Scientists: Journal Access
13:
AstraZeneca Cuts Again
12:
A Federation of Independent Researchers?
11:
A New Journal (With Bonus Elsevier-Bashing)
10:
Biomarker Caution
09:
Would I Take Resveratrol? Would You?
06:
Europe Wants Some of That Molecular Library Action
05:
What Makes a Beautiful Molecule?
04:
The Artificial Intelligence Economy?
03:
Information Density
03:
Bapineuzumab: An Alzheimer's Update
02:
"Taking the Ax to the Scientists Is Probably a Mistake"
March 2012
30:
Ciliobrevins: Digging Into Cell Biology
30:
Amylin on the Block
30:
Grad School Opportunity Costs? Not to Worry!
29:
Sloppy Science
29:
Pfizer: Making the Case for a Breakup
28:
Winning Ugly and Failing Gracefully
27:
Virtual Biotech, Like It or Not
26:
What's the Ugliest Drug? Or The Ugliest Drug Candidate?
23:
The Ultimate in Personalized Medicine
23:
Nativis Update
22:
Shortage of Blogification
21:
The Supreme Court Makes Me Smile
21:
Lilly Tries to Make It Up in China
20:
Personalized Medicine for Cancer? Try Every Cell.
19:
Running Out of Helium?
19:
Dealing with the Data
16:
Merck's CALIBR Venture
16:
Elsevier's RSS Feeds: Maybe a Not-So-Minor Complaint
15:
Side Effects - Lots of Side Effects
15:
Not Quite So Accelerated, Says PhRMA
14:
The Blackian Demon of Drug Discovery
13:
Nexavar Licensed by Force in India
13:
Verastem's Chances
12:
The Brute Force Bias
09:
Coaching For Success. Sure.
09:
Bad Day at AstraZeneca
09:
Double-Bond-S
09:
Are the Numbers Improving?
08:
Eroom's Law
07:
Eight Billion Dollars Apparently Isn't Enough
07:
Making the Move From Industry to Academia
06:
Drug Discovery for Physicists
06:
A Quick Note to Eli Lilly
05:
Department of Lots of Nerve (Patent Applications Desk)
05:
Trouble With a Boron-Containing Drug Candidate
02:
A Response From Sanofi
02:
Stem Cells in Texas: Quite the Business
01:
What Sanofi Thinks About You
February 2012
29:
Statin Safety
29:
Bias in Industry-Funded Trials in Rheumatoid Arthritis?
28:
Yes, The Research Works Act Is Dead
28:
One Does Not Simply Walk Into Fluorine Chemistry
28:
More on the NIH's Molecular Libraries Program
27:
Inside A Chinese Pharmaceuticals Maker
27:
Is the Research Works Act Dead?
27:
Pseudephedrine Made Easy. Kind of.
24:
An Actual Motivational Poster
24:
Independent Inventions
23:
The Worst Compound You've Ever Drawn?
23:
Remember When We Were Going to Eliminate Deaths from Cancer?
22:
Max Gergel's Second Odd Book
22:
Scaling Up a Strange Dinitro Compound (And Others)
21:
Rational Drug Design. Hmm.
21:
Ten Tons of Sodium And Just One Lake
21:
Ten Tons of Sodium And Just One Lake
17:
That Academic-Industrial Collaboration Panel
17:
Hepatitis C: Reality Intrudes
16:
When Reagents Attack!
16:
Imidazole-1-Sulfonyl Azide HCl: Look Out
15:
A Real Periodic Table - With Real Elements
15:
Eschenbach Says Market, Then Test
14:
An Elsevier Boycott
14:
Synthetic Electrochemistry: Who's Done Any?
13:
Pfizer Layoff This Past Weekend?
13:
Nobel Prizes in Chemistry For People Who Aren't Chemists
13:
Bexarotene for Alzheimer's
10:
The Terrifying Cost of a New Drug
10:
The Infinitely Active Impurity
09:
Guidance on Biosimilars
09:
Roger Boisjoly and the Management Hat
08:
Every Methods Paper Has a Table
08:
Buying Back Shares: An Admission of Defeat
07:
More Industrial Espionage
07:
Tau Spreads On Its Own?
06:
Academia and Industry, Suing Each Other
06:
Let's Start Off the Meeting With An Ad, OK?
06:
The Academic-Industrial Collaboration in Drug Discovery Panel: Today
06:
Glass Structure, Atom by Atom
03:
How the Andrulis Paper Got Published
03:
AstraZeneca in Waltham
02:
Fluorine NMR: Why Not?
01:
AstraZeneca Layoffs and Closings
01:
Potassium Hydride Is Not Your Friend
01:
Smugness as a Warning Sign
January 2012
31:
The Andrulis Paper's Fallout
31:
AstraZeneca Cutting Even More?
31:
The Future of Pharma? Yikes.
30:
(Un)stoppable Pixantrone
30:
The Key to Everything? Not Quite.
27:
Roche Goes Hostile for Illumina
27:
Arsenic Bacteria Ride Again. (Or Don't).
26:
Science, A Zero-Sum World, and the State of the Union
26:
Putting a Number on Chemical Beauty
25:
Panel on Academic-Industrial Collaboration in Drug Discovery
25:
Open Office Plans - A Question or Two
25:
Comments (And Everything Else) Are Back
23:
Comment Trouble
23:
This All Too Open Office
23:
Strangest Presentation You've Seen?
20:
Worst Lecture of All, Or Greatest?
20:
Alnylam Cuts Back Hard
20:
Zelboraf: Treat One Cancer, Speed Up Another?
19:
Dapagliflozin Goes Down (For the Last Time?)
19:
Takeda Announces Cuts
19:
The Research Works Act: One (Two!) Against and One For
18:
Selling Sanofi's Compounds on the Side
18:
Fun With Epigenetics
17:
Warp Drive Bio: Best Name or Worst?
17:
Newhouse Research
17:
Down With the Research Works Act
16:
Defending Das' Resvertrol Research. Oh, Come On.
16:
Biogen: A "Decimated" Pipeline?
13:
Dealing With Dishonesty
12:
A Resveratrol Research Scandal. Oh, Joy.
12:
Sanofi's Bridgewater Site - Closing This Week?
12:
Welcome To the Jungle! Here's Your Panther.
11:
Ten Years of Science Blogging. Already?
09:
The JP Morgan Myths
09:
A Look Into the Future?
06:
SciFinder Access For the Unemployed
06:
Do We Believe These Things, Or Not?
05:
Reaction to Andy Grove's Clinical Trial Proposals
05:
Lead-Oriented Synthesis - What Might That Be?
04:
The Changing Literature
04:
Osiris And Their Stem Cells
03:
2012 In Startups
03:
That's Sir Andrew to You
03:
The Research World Staggers Back to Work
December 2011
28:
Nowhere to Go But Up?
28:
The UCLA Lab Fatality: Criminal Charges Filed
23:
Media Note
23:
Holiday Break
22:
More From Hua - A Change of Business Plans?
22:
Merry Christmas, Fred
21:
Chemistry, The Movie!
21:
AstraZeneca's Problems
20:
Best Paper You Read This Year?
19:
Trifluoromethylation, The Easy Way?
19:
Deals of the Year in Biopharma (Bonus: Names That Can't Happen)
15:
More on Chinese Pharma Espionage
15:
Chinese Pharma Espionage?
14:
Burzynski Revisited
14:
An NMR Poster
14:
Now That's A Catalyst
13:
Nothing Says "Chemistry" Like Nonsense!
13:
The Sirtuin Saga
12:
Don't Dose That Patient Until You Pay Up
09:
Pharma Overview
09:
Drugs, Airplanes, and Radios
09:
Uranium, Eh?
08:
The Loss of the Middle (Drugs and the People Who Find Them)
07:
Plan B and the FDA: Unprecedented
07:
Merck in China
06:
Novartis: No More Neuroscience
06:
Riding to the Rescue of Rhodanines
05:
Naming Your Company After Yourself
05:
More on Alex Denner
05:
Rexahn Rides Again
02:
Blog Traffic: A Thank-You
02:
Not Just FDA-Bashing?
02:
Acronym-Fest: GSK and Its DPUs
01:
Worst Biotech CEO of 2011?
01:
Nevirapine: Not Chiral. Paper: Not Right. Editorial Staff: Not Doing Their Job
November 2011
30:
The XMRV Story Is Not Getting Any Saner
30:
Lipitor Expiration Day
30:
Finding Even More New Reactions By Looking For them
29:
Podcast on Avastin
29:
The Burzynski Cancer Treatment
29:
A "Things I Won't Work With" Request
28:
Amgen's New Patent: Explanations, Anyone?
28:
So What Did Lipitor Do for Pfizer? Or Its Shareholders?
24:
Happy Thanksgiving
23:
Lab Preparation: Key Lime Pie
22:
The Mouse Trap
22:
Regeneron Finally Makes It to the Market
21:
Avastin Coverage, Amended
21:
Of Drug Research and Moneyball
18:
Avastin's Metastatic Breast Cancer Approval Revoked
18:
Pushing Onwards with CETP: The Big Money and the Big Risks
18:
Two From Glaxo's Old Days
17:
Business Note: Random Promotion, Anyone?
17:
Brain Cells: Different From Each Other, But Similar to Something Else?
16:
Ray Firestone's Take On Pharma's Plight
16:
Virtual Pharma, Revisited
16:
Proteins in a Living Cell
15:
Managing For Motivation, The Simple Way
15:
Exit Icahn, Enter Denner?
15:
Geron, Stem-Cell Pioneers, Drop Stem Cells
14:
Translation Needed from Execulinga
14:
Anticoagulants, One After Another
11:
Things I Won't Work With: Hexanitrohexaazaisowurtzitane
10:
Makena's Market. Or Lack of One.
10:
Resveratrol in Humans: Results of a Controlled Trial
09:
KV Pharmaceutical's Latest Makena Move
08:
In-Sourcing Chemistry: Lilly and AMRI
08:
Targacept's Antidepressant Fails, And How
07:
Where's the Best Place to Apply Modeling to Drug Discovery?
07:
Rating A Massive Pile of Compounds
04:
Table Of Content Graphics, Mocked
04:
What's the Hardest Thing?
03:
Verastem Goes Public: Why Not?
03:
Medivation Comes Through With MDV3100
02:
Sanofi Announces Layoffs
02:
Tiny, Tiny Molecules for MS
02:
Faking Two Papers A Month. For Seven Years.
01:
Exelixis Fights City Hall, and City Hall Looks Like Winning
01:
President Obama Orders the FDA to. . .Do What, Exactly?
October 2011
31:
"You Guys Don’t Do Innovation. The iPad. That’s Innovative"
31:
A Note About Identity Spoofing
31:
Very Likely Not Real, But Still. . .(The E-Cat)
28:
Merck, And What Used to Be Schering-Plough
27:
Liquid Handling
27:
Fish Nor Fowl
26:
Francis Collins Speaks
26:
A Note to Andy Grove
25:
Novartis Announces Cutbacks
25:
NCPharma: Changing the Drug Industry How, Exactly?
24:
The Layoff Project
24:
Tossing Out the 1920s Hydrogenators: Can It Be Done?
21:
Does Anyone Want the NIH's Drug Screening Program?
21:
The Force of Cluelessness
20:
Georgia Tech Forgets How to Draw Structures
20:
Abbott Cuts the Drug Business Loose
19:
Reorg at Merck? (And a Complaint about Wall Street)
18:
A New Book on Chemical Patents
18:
Cyclodextrin's Day in the Sun
17:
The Singularity, Postponed
17:
Harvard to the Rescue
14:
Amgen: Brace Yourselves
14:
Avastin: False Hope for Metastatic Breast Cancer
13:
XMRV - Work Went On
13:
Freedom of the Press: Science Reporting Division
12:
siRNA - Toxicity in the Eye?
11:
Brow-Furrowing Chemical Ads
11:
Too Many Cancer Drugs? Too Few? About Right?
07:
Different Drug Companies Make Rather Different Compounds
06:
Is Alzheimer's An Infectious Disease? The Spread of Protein Misfolding
05:
A Quasicrystal Nobel Prize
04:
Podcast Interview on Drug Discovery
04:
Yep, That's A Nobel Prize, Right There
04:
XMRV: This Is Not Good
03:
Chemistry Nobel Time
September 2011
30:
Patent Trolling, Money and Fun
29:
XMRV: Over With and Done?
29:
Ah, Remember Those Days? How Will We Remember These?
28:
Andy Grove's Idea For Opening Up Clinical Trials
27:
So, How Come You're So Darn Lucky, Eh?
27:
What Layoffs Have Done
26:
Predicting Toxicology On A Chip?
23:
"The Smarter You Are, The More I Will Hate You"
22:
The Latest Sirtuin Controversy
21:
Big Sirtuin News
21:
Pulling Molecules Apart, For Fun
21:
Finding New Reactions By Looking For Them
20:
Honest Research in China
20:
Foldit Notches a Protein Structure Success (And Some Failures)
19:
GSK and McLaren: Two Different Worlds
16:
Day Off (In the U.K.)
15:
Targets to Avoid (Or That We Wish We Had)
15:
Terra Slightly Less Incognita
14:
Lilly's Open Screening Program: An Update
13:
Conferencing
13:
Fifty Years of Med-Chem Molecules: What Are They Telling Us?
12:
From the RSC/SCI Symposium: A Med-Chem Anomaly
12:
The Scientific Literature Gets Kicked Around
10:
Conference Travel, With Blogging
09:
China's Home-Grown Insanity?
08:
Publishing, Perishing, Buying and Selling
07:
Get Yer Rhodanines Here
07:
Hard, Hard Work in the Lab
06:
A Dish Best Served Cold
06:
Chronic Fatigue: Enough Energy Left for Death Threats, Anyway
02:
How Many New Drug Targets Aren't Even Real?
01:
GlaxoSmithKline Reviews the Troops
August 2011
31:
The Finest Retraction Notice Ever?
31:
China's Pharma Ambitions: Hua Pharmaceuticals Responds
30:
Why Isn't There an ArXiv For Chemistry?
29:
Chinese Pharma: No Shortage of Ambition, Anyway
26:
Kibdelomycin, A New Antibiotic. In A Way.
26:
Design a Molecule, Win an IPad (Which is More Than You Usually Get)
25:
Crazy Shape-Shifting Bullvalenes
24:
Disappearing Information, Courtesy of Aldrich Chemical
24:
What Are Impact Factors Doing to Chinese Science?
23:
SRT1720: Good (And Confusing) News for Obese Mice
22:
DRACOs: New Antivirals Against Pretty Much Everything?
19:
Day Off - Some Links and Some Ancient Greek
18:
Is Anyone Doing the Pfizer Screening Deal?
18:
The NIH Wonders About the Future of Biomedical Workers
17:
New Ways to Fluorinate
16:
Screening Quickly Through the Mutants
16:
Is Carl Icahn Going Away?
15:
mINDY Mice - No Obesity, No Diabetes?
12:
A Startlingly Good Leukemia Trial
11:
In Which We Learn Lots About Wine Swirling
11:
Lundbeck Cutting R&D
11:
Scientific Retractions: A Growth Industry?
10:
The Economics of the Drug Industry: Big Can't Be Big Enough?
09:
Drug Research Areas You Wish You'd Never Heard Of
09:
What An Offer
08:
More On Cancer Drug Shortages
08:
Read the Comments
08:
Gilenya's Price
05:
Bernard Munos Rides Again
04:
Does Anyone Want Axanum?
04:
Dendreon: Watch the Cost Curve Being Bent
03:
What the Bottom of the Barrel Looks Like
03:
A Former Pfizer Executive Finally Trashes Pfizer's Strategy
02:
Merck, RNAi, Alnylam, And So On
02:
Merck Moving Research From Rahway?
01:
Laquinimod Fails For Multiple Sclerosis
01:
Chinese Research: Not Quite the Juggernaut?
July 2011
29:
Merck Announces More Big Cutbacks
29:
2011 Drug Approvals Are Up: We Rule, Right?
28:
The Secret History of Pfizer
28:
Massive Piles of Faked Data - But Right On Time
27:
Bait And Switch For Type B GPCRs
26:
Data Handling in Collaborations
26:
Precious Metal Time
26:
Alzheimer's: The News Is Not Getting Better
25:
Broader Impacts Indeed
22:
A Few More Victories Like This, And We Will Be Undone
22:
Right Up Next to Academia
21:
The Public Perception of Chemistry
21:
Drugs for Multiple Sclerosis: Worth the Price, Or Not?
20:
Will Macrocycles Get It Done?
19:
Sezen / Sames: What Does it Say About Grad School?
19:
Back to Blogging
13:
Book Review: The Quest for the Cure
11:
On and Off
08:
The Sames / Sezen Fraud Case: Holy Cow
08:
The Duke Cancer Scandal and Personalized Medicine
07:
Phenotypic Screening For the Win
06:
A First Step Toward A New Form of Life
05:
Fakery, As Revealed By Figures
02:
Innovation and Return (Europe vs. the US)
01:
Avastin and Medicare
01:
The Histamine Code, You Say?
June 2011
30:
Pfizer Reverses Course in Sandwich - A Bit
30:
An Unethical Clinical Trial
30:
Transcendental Meditation: Hold That Paper!
29:
Avastin At the FDA Today: Passion Should Lose
29:
For Responsible Stem Cell Reporting. . .
28:
Drug R&D Spending Now Down (But Look at the History)
28:
DTC Advertising: Is That Where Things Fell Apart?
27:
Making the Numbers Confess
27:
The Evolution of Resistance: Are We Doing It Wrong?
24:
Telling Everyone What It's Like
24:
Generic Drug Warning Labels: The Supreme Court Speaks
23:
Cladribine Is Gone
22:
The NIH and Conflicts of Interest
21:
Senator Hatch And His Wonderful Industry
20:
Not Looking So Good At Eli Lilly (or AstraZeneca)
17:
How's All That Cost-Cutting Working Out?
16:
What Translational Research Should Academia Do?
15:
High Pressure - The Good Kind
15:
The Failure of Modern Medicine?
14:
A Shortage of Cancer Drugs?
14:
The Uses of Disorder
13:
Block That Review
10:
Chem-Geekery: Name Reactions You've Never Run
09:
Cardiac Hope and Cardiac Hype
09:
Academic Drug Discovery: A Survey
08:
Garage Biotech: The Book
08:
Roche Prevails Over Stanford
07:
Even Worse Than Reality
07:
Murine Viruses and Chronic Fatigue: Does the Story Continue
06:
Underused Lab Solvents
06:
XMRV and Chronic Fatigue: Down For More Than the Third Time
03:
More Insider Trading at the FDA?
03:
Another Two-Person Drug Company
02:
Biomarkers, Revisited. Unfortunately.
01:
Return of the Arsenic Bacterium
May 2011
31:
Extreme Outsourcing
30:
Memorial Day
27:
Niacin's Unexpected Flop
27:
The Ethics of Avastin
26:
Pfizer's Brave New Med-Chem World
25:
Getting Rid of Pesky Chirality
25:
Pfizer's Layoff Dance
24:
How Others See Us (And How We See Them)
24:
Maybe It Really Is That Hard?
23:
Inadvertent Day Off
20:
What Would You Get Rid Of?
20:
Like Charges, Er, Attract?
19:
Get Yer Telomeres Measured, Step Right Up
19:
Avandia Goes Out
18:
Fenofibrate: Good For Much?
18:
Funding People, Not Projects?
17:
Quis Custodiet Ipso Custodes?
17:
Imperfect Pitch
16:
A Google Oddity
16:
Ups and Downs
13:
Process Chemistry Makes the Headlines
12:
Icahn's Biotech Adventure
11:
Writing About Science, and Liking It
11:
In Memoriam, Two Chemists
10:
A Complete Diversion: Purple Compounds
10:
Phase II Failures
09:
What Medicinal Chemists Really Make
06:
The Top 100 Chemists?
06:
In Which I Do Not Lose It, For Once
05:
Excel and Exceed, Y'all
05:
When Lipitor Goes Generic
05:
Translation Needed
04:
GSK and Alli. Not Quite Working Out
04:
What Autism Epidemic?
03:
Let the Healing Begin
03:
Lucentis and Avastin: Results
03:
A Look Inside the Compound Collections
02:
Great Moments in Journal Editing
02:
Pfizer: Breaking Up Is Hard to Do
02:
A Brief Note on Current Events
April 2011
29:
Keep On Scrollin'
29:
Merck: How to Spend the Money
28:
Conference Time
28:
Pfizer Layoffs Today
28:
Just A Few More Month's Work, That's All I'm Asking Here
27:
Off the Beaten Track. Way, Way, Off.
26:
AstraZeneca Tears 'Em Down
26:
Graphical Crankiness
26:
So Much For Natural-Product Nevirapine
25:
The PhD Problem: A Global Perspective
25:
Now They Tell Us
22:
Day Off
20:
Return of the Magic Methyl Group
20:
Nothing Personal
18:
Merck and J&J Finally Come to Terms
15:
Selenium In a Drug Structure: Why Not?
14:
Coming Up in the World With CROs
14:
Total Pharma Job Cuts
13:
The Fox's Lament
13:
Hedgehogs and Foxes Holding Erlenmeyer Flasks
12:
Scientific Fraud: How Often and How Much?
11:
R&D Is For Losers?
08:
Roche and Stanford: Academia v. Industry?
07:
What's Really Killing Pharma
07:
More Zeroing In On Breast Cancer Cells
06:
Westphal Leaves GSK
05:
So, You Thought Breast Cancer Was Complicated?
05:
In Which I Reminisce About the Prins Reaction, Chemical Abstracts, and John Keats
04:
Surely You Have Something Else to Do
04:
Update on Avastin and Lucentis
01:
Live Long and Prosper (and Be Bright Yellow at the Same Time)
March 2011
31:
Your Comments on the NIH's CNS Drug Program?
31:
What If Those Wonderful Results Are Wrong?
30:
KV Pharmaceuticals and Makena: The FDA's Move
30:
Insider Trading at the FDA
29:
Modeling and Structure
29:
The NIH Goes For the Gusto
28:
Value in Structure?
25:
The Supreme Court Slams Big Pharma? Not Exactly.
24:
More on KV and Makena's Pricing
23:
Laboratory Sabotage?
23:
More Crankitude: All Natural This Time
22:
Crankitude: A Quick Glossary
22:
A 200-Proof Shot of Medicinal Chemistry
21:
The Small Drug Companies And the Big Ones
21:
A Radiation Chart to Clip and Save
18:
Brave New Office
17:
Block That Metaphor!
16:
More Bad News in the UK: Novartis Horsham
16:
Pfizer Moves Antibacterials to Shanghai
16:
Potassium Iodide Pills
15:
Quick Japan Update
15:
Bias And How to Deal With It
15:
Pfizer: Bigger, Um, Isn't Better?
14:
Japan
11:
Makena's Price: What to Do?
10:
Benlysta for Lupus
10:
The Cost to Develop a Drug: Your Own Numbers?
10:
Public Outreach
09:
What A Fool Believes
08:
More On the Postdoc Situation
08:
The Pfizer Air Force
08:
That $43 Million R&D Figure
07:
The Costs of Drug Research: Beginning a Rebuttal
04:
Science: Good For Anything Else?
03:
A Postdoc's Lament
02:
It's Worth It to Know That There Are Others
02:
MannKind: It's Not Looking Good
02:
Now, That's An Abstract
01:
The Pfizer Sandwich Closure
01:
Use Avastin! Don't Use Avastin!
February 2011
28:
Down In Phase III. Again.
25:
Things I Won't Work With: Chlorine Azide
24:
Is Big Pharma Killing Startup Companies?
23:
Gonna Focus on Re-Engineering the Tools for the Process
23:
Want to Live Where Merck Used to Work?
22:
Oncology Follow-Up Trials
22:
Science and Revolution
21:
Cutting The Cuts to Save Money on the Money-Saving
18:
Smell The Vibrations? Fruit Flies Might Be Able To. . .
17:
Health Care Reform and the Drug Industry: How Goes It?
16:
The Key Player in the Sanofi-Genzyme Deal Speaks Out
15:
Noted, Through Massive Self-Restraint, With Almost No Comment Whatsoever
14:
New Cures! Faster! Faster!
11:
Merck, J&J, and Remicade: Waiting Nervously
11:
Drug Problems: A Diagnosis
10:
The Top 200 Drugs
09:
Thallium Poisoning? In This Day and Age?
09:
Fanapt: Not Paying Out
08:
Too Much Outsourcing: Has the Line Been Crossed?
08:
Whistleblowers: Paid Too Much?
07:
Not Letting Pfizer's UK Site Go to Waste?
07:
Fragments Versus DOS: A Showdown
04:
Merck's Strategy vs. Pfizer's
03:
Pfizer's CEO Speaks
01:
Pfizer Part Two: Cuts at Groton
01:
Bad News: Pfizer Closes Site in Sandwich
01:
The NIH's New Drug Discovery Center: Heading Into the Swamp?
January 2011
31:
What's the Most Worthwhile New Drug Since 1990?
31:
Sanofi's PARP1 Inhibitor Misses
28:
And a Quick Political Note
28:
Arsenic in DNA: The Kinetic Argument.
28:
Friday Mental Health Break: "Bad Project"
28:
What The Referees Really Think
27:
Another Snow Day
26:
Abbott's Cutting Jobs
26:
Those Me-Too Drugs
25:
Weirdness: A Cold Fusion Demonstration?
25:
Weirdness: Montagnier Again, Teleporting DNA
24:
Not Enough Progress Against Cancer?
21:
Oh, And While You're At It. . .
20:
Freedom to Operate
20:
Merck's Vorapaxar: Bleeding, Indeed
19:
Dogs and Ponys
18:
Retractions: Why The Secrecy?
17:
Reboxetine Doesn't Work. But That's Not the Real Problem.
14:
Fishing Around for Biomarkers
13:
Merck's Thrombin Antagonist In Trouble
13:
Sanofi's Slow-Motion Takeover of Genzyme
12:
Snow and Chance Happeneth To Them All
12:
Gassing Your Crystals
11:
The Life of a Paper
11:
XMRV: It's Ugly, But That's Science
10:
Has Luc Montagnier Lost It?
10:
Ahem: "Sell Gobs of Dope"?
07:
More On Homemade Street Drugs
07:
The PhD Problem
06:
Storage of Industrial Chemicals, Gone Rather Wrong
06:
MMR Vaccine and Autism: Lies, All Lies
05:
How to Fund a Nonprofit Drug Company - And Others?
04:
Detecting Single Cancer Cells
03:
Drug Approvals 2010
03:
And So, 2011
December 2010
30:
Another Cold-Weather Recipe: Chicken Pot Pie
28:
A Cold-Weather Recipe, By Request: Onion Soup
27:
Weather Delay
22:
Holiday Break
20:
Putting Some Numbers on Peer Review
17:
Jobs Roundtable Recap
17:
Politics in the Lab
17:
The Avastin Decision: A Reality Check
16:
Science Jobs Roundtable - Day Four
15:
What A Paper Doesn't Have In It
15:
Chemistry Jobs Roundtable: What About Tenure?
15:
Chiral What? Chiral How?
14:
Too Many PhDs, Revisited
14:
The Solid Phase
13:
Big Pharma's Lost Stock Market Decade
13:
Chemistry Jobs, Present and Future
10:
Have Pfizer's Investors Had Enough?
09:
The Escondido House of Explosives Goes Up - Live
09:
So What's Going On With Peer Review, Anyway?
08:
NASA's Arsenic Bacteria: A Call For Follow-Up Experiments
08:
Fluorination Without Tears. Or Panicked Shouts.
07:
Arsenic Bacteria: Does The Evidence Hold Up?
06:
A Quick Glassware Question
06:
Exit Kindler
03:
Not On My Street - I Hope
03:
Going to Let Someone Else Do This One
03:
Guess the Author: Revealed
02:
Life With Arsenic: Who'd Have Thought?
02:
Amazing Stuff! Guess Where It's From. . .
02:
HIV Therapies: A Thank-You
02:
Ghostwriting On the Larger Scale
01:
Novartis, Meet Novartis (Job Cuts or Not?)
01:
The Sames-Sezen Case: The Feds Speak
01:
Resveratrol (SRT501): Development Halted
November 2010
30:
More Advice From Andrew Witty
29:
Design Your Own Lab Course
25:
Blogging Break
24:
Holiday Organic Synthesis: Chocolate Pecan Pie
23:
Of Deck Chairs, Six Sigma, And What Really Ails Us
22:
Spending and Publishing
19:
Merck's CETP Compound: Still Alive, But The Big Fun Awaits
19:
Novartis and the Labs of the Future
18:
Halaven: Holder of the Record
17:
Roche Has Problems - But RNA Interference Has More
17:
More Fraudulent Papers Coming From the US?
15:
Things I Won't Work With: Nitrotetrazole Oxides
15:
Kitchen Chemistry Gear
12:
99% Yield? That, Friends, Is Deception
12:
And Now, the Retractome
11:
And One Was Just Right?
11:
Comment of the Day: Outsourcing and Architecture
10:
An Outsourcing Blast
09:
Where Drugs Come From: By Country
08:
Epigenetics: The Code Isn't The Object
08:
Engaging the Public?
05:
Peer Review's Problems
04:
Finally, An Alternative to Palladium. About Time.
04:
Where Drugs Come From: The Numbers
03:
TRIM21: A Cure For the Common Cold? Maybe Not. . .
02:
Good Old Medicinal Chemistry: What Can You Get Away With?
01:
Are Genes Patentable Or Not?
01:
Drugs At Home
October 2010
29:
A Whistleblowing Record
28:
Shine A Light
28:
ACS Survey - Or Something Else?
27:
Graphene Oxide as a Reagent
27:
Lethal Injection: A Case For the FDA?
26:
Dapsone Prolongs Life? Well, In Nematodes It Does. . .
26:
Enthalpy and Entropy Again
25:
Settle A Bet
25:
If You're Not Excited, Sit Down
25:
Lorcaserin's Complete Response
22:
The Latest Technology
22:
Keeping Track Of All Those Chemicals
21:
Laser Nematode Surgery!
21:
Apotex's Plavix Adventure: Four Years Later
20:
Is Cancer A Disease of the Modern World?
19:
Trusting the Medical Literature?
18:
Palladium Couplings: You Can't Run Them All
18:
So, How Well Does Winning a Nobel Set You Up?
18:
Merck vs. J&J: Wait For It
15:
Those Chemistry Bloggers
14:
Whoa! Time to Clean the Fishtank! Uh, Root Canal Appointment! Look at the Time!
14:
Conference Thoughts
13:
A Cautionary Tale
13:
Well, Okay: The Ugliest Biopharma Sites?
12:
Exelixis Grabs A Life Preserver
12:
Most Picturesque Biopharma Location?
12:
Drug Discovery History
11:
Princeton's New Chemistry Building
11:
Back to Philadelphia
11:
Meeting Time
08:
Does Resveratrol Really Work? And Does SRT1720?
07:
The Layoff Picture
07:
More on Garage Biotech
06:
A Nobel For Palladium Couplings, At Last
06:
Chemical Biology: Engineering Enzymes
05:
Chemical Biology: Plastic Antibodies?
04:
Spamming For Site Shutdowns. Sheesh.
04:
Sanofi Goes Hostile
01:
Three Times Is Enemy Action
September 2010
30:
The Hours You Put In
28:
Open Thread
28:
Wisterone: A Structure I Can't Believe
28:
Nobel Season 2010
27:
Charges in the TMS Diazomethane Case
27:
Workhorse Reactions
24:
Serendipity in Medicine
24:
Avandia Goes Down: A Research Rant
23:
Delightful, But It Apparently Works
23:
Chemical Biology - The Future?
22:
Synthetic Chemistry: All Mined Out?
21:
Want To Make an Amide? Have I Got Good News For You!
20:
Sodium Hydride As Oxidant, Again?
20:
J. Whoozat Sci.
17:
Put In Another Methyl Group: A Villanelle
17:
Spread of the Pun Virus
17:
The Life of a Key Opinion Leader
16:
Live-Blogging Arena's FDA Committee Hearing
16:
Six Sigma in Drug Discovery? Part One - Are Chemists Too Individual?
15:
Intermediates
14:
Lorcaserin in Trouble
14:
How Much Compound?
14:
A New Way to Approve Drugs
13:
You May Not Be Interested In It - But It's Interested In You
10:
Sanofi-Aventis: It's $69/Share, And That's Where It Stays
10:
Cut-and-Paste Your Way to Publication
09:
PLX4032: The Good News and the Bad News
09:
Merck vs. J&J: It's Come to This, Eh?
08:
Ancient Chemistry Comes Back to Life?
08:
Outsource to China, Then Move There?
07:
China Outsourcing: Getting More Expensive, Fast?
07:
Columns Outside The Doors
06:
Day Off
03:
Metformin Against Cancer?
02:
Posters and Pickiness
01:
How Long Would It Take - If Everything Worked?
01:
Scientia Est Experientia
August 2010
31:
Nanopowders?
30:
Avastin For Metastatic Breast Cancer: The Whole Story
30:
Roche: Layoffs, or Rumors?
30:
How About The Same Price You Turned Down Before? Hmm?
27:
Blogroll Update
27:
Not Your Usual FDA Hearing
27:
How Much is the PI To Blame?
27:
Sanofi-Aventis and Genzyme: Walking Away?
26:
Vinca Alkaloids, And Where They End Up
25:
GSK's Response to the Sirtuin Critics
25:
Where Are the Cures?
24:
Gegen die Dummheit . . .Well, Guess Who Wins, Again
24:
XMRV? Or Umpteen Other Viruses? Or What?
24:
Alzheimer's: Down With Amyloid?
24:
Housekeeping Note
23:
Lunch at the Boston ACS Meeting
23:
Kurzweil Responds
20:
Going Hollywood
20:
Reporting on Alternative Careers
19:
Not The End. Not At All
18:
Reverse-Engineering the Human Brain? Really?
18:
Lilly's Gamma Secretase Inhibitor for Alzheimer's: Worse Than Nothing
17:
Avastin: Taking It Back
16:
Is Genzyme a Buyable Company At All?
16:
Cancer Cells: Too Unstable For Fine Targeting?
13:
By The Way. . .
13:
Alzheimer's Markers and Collaboration
12:
Resveratrol (SRT501): Buy Now - Why Wait?
12:
MannKind and Seaside 88?
11:
If You're Not A Chemist - What Next?
10:
All Quiet on the Genzyme Front?
09:
Maybe We Should Make It More of a Game
06:
Organic Chemistry: A Lack of Challenges?
05:
Metal-Free Coupling Reactions: Now Wait A Minute. . .
04:
Running Your Fingers Over A Single Molecule
03:
Know How to Make Praziquantel? Tell The World.
02:
Charles River Gives Up
02:
Joy
July 2010
29:
Craig Venter, Venting
29:
Let's Just Spread This Deal Out All Over the Paper, Why Don't We?
29:
New from OSI / Astellas
29:
Open-Source Pharmaceutical Babble
28:
Out in the Public
28:
PPAR: A Veil Is Lifted, At Last
28:
Genzyme: On the Other Hand. . .
27:
How Sleazy It Can Get
27:
Genzyme Telling Sanofi-Aventis to Buzz Off?
27:
Alzheimer's and Amyloid, Again
26:
Biosimilars: Not Easy, But Not Impossible, Either
23:
Aventis: Is It Genzyme?
23:
Vivus, Qnexa, Arena, Lorcaserin and the FDA
22:
Back in Business
13:
Midsummer
13:
Avandia: Was the Evidence Buried?
13:
Hmmm: The Gates Foundation Bails
12:
Natural Products: Not the Best Fit for Drugs?
09:
Lechleiter's Prescription for Science
09:
The Horror Of Asking For Data
08:
Why Close One Research Site Over Another?
07:
Merck Site Announcements - Closures and Otherwise
07:
XMRV and Chronic Fatigue: You Thought You Were Confused Before
07:
Drug Prices in the US: Not So High After All?
06:
Commenting On Scientific Papers: How Come No One Does It?
05:
More From the Fourth
05:
Holiday
02:
Sanofi-Aventis Acquires. . .Somebody?
01:
GSK's Biotechy World
01:
"Doctor's Data": Telling the Truth and Getting Sued For It
June 2010
30:
Another Zero-Palladium Delusion?
30:
How Not To Do It: Hydrogen Gas Mixtures
29:
Stable Helical Peptides Can Do It All?
29:
The Ideal Synthesis
28:
Maitotoxin: It's On, All Right
28:
That Schering-Plough Lawsuit Isn't Going Away
25:
What To Do With The Not-Quite-Worthless
24:
Fungal Structures to the Rescue
24:
All Those Worthless Papers
23:
Lilly's Statin - Yes, It Is 2010
23:
Exelixis Gets a Compound Back
22:
Andrew Witty's Advice
22:
Free Software
22:
Mylotarg and the FDA
21:
Cease and Desist
21:
Flibanserin: Not a "Female Viagra" At All
18:
Chemistry Employment in New England?
18:
The Economic Impact of the Genomic Revolution's Failure
18:
What Has Bioinformatics Ever Done For Us?
17:
Checking the Business Ratios
16:
Merck Layoffs - Underway?
16:
Sparteine and Other Fine Chemical Shortages
15:
Paying People to Take Their Medications
15:
California vs. Nature
14:
Angiotensin Receptor Blockers and Cancer: For Real?
14:
Looking Back at the Genome
11:
Eli Lilly, Meet Eli Lilly. Topic: Outsourcing!
11:
Alzheimer's: Extracting Data From Failed Trials
10:
Nativis: In Which the Distant Footfalls of Lawyers Can Be Heard
10:
Coming Soon
09:
Running Out of Decent Molecules to Patent?
09:
Raising Your HDL - Through the Brain?
08:
The Atlantic Monthly on Drug Pipelines
08:
Anyone from GSK Interested?
08:
Ipilimumab (And Progress Against Cancer)
07:
Again, What's It Worth to You?
04:
OCD Linked to the Immune System?
04:
Nativis: Waiting and Seeing
03:
Eribulin Gets Reviewed, Finally
03:
Sequenom: Faking It
02:
The Power of Photons, You Say?
01:
The Truth Shall Make Ye. . .Unhappy?
May 2010
28:
Scientific Discovery: Getting Older (And Less Lonely)
27:
Pfizer Halts a Trial Early - On Good News
27:
Max Gergel's Memoirs
27:
Golden Ages Are Where You Find Them
26:
Albany Molecular Cuts - In the US, Anyway
26:
"Better Educated" in China?
26:
India's Research Culture
25:
A Word to the Wise
24:
What's the Condensation Record?
24:
Great Moments in Heterocyclic Chemistry
24:
Martin Gardner, RIP
21:
Friday Book Recommendation
20:
A Synthetic Genome; A New Species
20:
Floyd Landis: The Isotopes Weren't Lying, After All
20:
Ang. Chem. Gets Weirder Every Day
20:
Astellas and OSI: Nothing like MLNM/Takeda?
19:
Pyridines and Dichloromethane
19:
Manning the Phones
19:
Another Set of Eyes
18:
Biosimilars: Not So Dang Easy
18:
Astellas Buys Out OSI
17:
The Memory Goes Because. . .the Acetyl Groups Go?
17:
Modeling in Drug Discovery: Questions?
14:
How Not to Do It: Acetylene Cylinders
14:
DCA And Cancer: More Results
13:
You Don't See Many Names Starting with "Tellura-"
13:
Layoff at Takeda
13:
China's Future
12:
A Quick And Nerdy Question
12:
Insulin Degrading Enzyme's Turn in the Spotlight
11:
Regulatory Approvals in the US versus Europe
10:
Unlovely Polyphenols
10:
Bill Gates Put Some Money On Schrödinger
10:
Malcolm Gladwell on Synta and Oncology
07:
Environmental Cancer?
07:
Things I Won't Work With: Small, Smelly Isocyanides
06:
Perverse Incentives In Clinical Trials
06:
Unintelligent Design
05:
Intermune: Right Back Down Again
05:
Steve Nissen vs. GlaxoSmithKline
04:
Merck Rumors?
04:
Another Proposal For the Scientific Literature
03:
SRT501 - A Trial Suspended
03:
The Collapse of Complexity
April 2010
30:
Phthalate: A Natural Product? Sure 'Bout That?
30:
Rating The Chemical Offerings
30:
Rosetta@Home
29:
Chemistry In (Ahem) Everyday Life
29:
Curse of the Plastic Tubes
29:
The Scent of Food Is Enough?
29:
Treatment INDs - For Any Generex Fans Out There
28:
Pfizer's Future: Biotech Followups
28:
Delivery Via Kindle
28:
Sirtris's Compounds: Everyone Agrees?
28:
Homemade Morphine?
27:
Merck Closes a Site
27:
Of Cambridge, MA Interest Only
27:
Masses of Data, In Every Sample
26:
Maitotoxin Revisited
26:
Charles River Buys WuXi
26:
Report from C&E News
21:
Two Bad Ideas
20:
Bits And Pieces
19:
More on C&E News
18:
C&E News - A Few Questions
16:
A Landmark In Clinical Trial Data Interpretation
16:
Generex: Who Buys This Stuff, Anyway?
15:
A Re-Org at Novartis
15:
A Tiny Little Presentation Tip
14:
Colchicine's Price Goes Through the Roof
13:
Novartis, Roche Threaten To Leave the UK
13:
Too Many Consulting Jobs Work This Way
12:
Prediction Markets, Idea Sharing, and So On
09:
The Crowd Goes Wild
09:
Dundee's NMT Inhibitors for Sleeping Sickness: An Update
09:
Patent Chart Update
08:
ACS Med Chem Letters
08:
Let's Sequence These Guys
08:
ACC2: Great Metabolic Target, Or Total Bust?
07:
Pfizer's Golden Age
07:
Generex and Their Insulin Spray: Just Hype?
06:
A Brief and Not At All Intemperate Evaluation of the Current Literature
06:
Take These?
06:
Let's Hope They're Right
05:
Rapamycin for Alzheimer's?
05:
Sickened by an Engineered Virus?
02:
Day Off
01:
Exelixis: Hmmmm.
01:
About Time
01:
Good News Versus Sleeping Sickness
01:
What Do Nanoparticles Really Look Like?
01:
Ardea's Gout Drug Progresses
March 2010
31:
Only Three Patents? Really?
31:
Darn It All
30:
The Ariad Decision and Written Description
30:
Myriad's BRCA Gene Case: Wait For It
30:
Animal Studies: Are Too Many Never Published At All?
30:
GeneVec's Pancreatic Cancer Therapy Crashes
29:
Antisoma's Phase III Disaster
29:
Compounds and Proteins
26:
Diminishing Returns
26:
Try It At Home
26:
Privileged Scaffolds? How About Unprivileged Ones?
25:
If You Need Some Lab Equipment. . .
25:
The Problem With Research on Aging
25:
Nanoparticles and RNA: Now In Humans
24:
Privileged Scaffolds
24:
Drugs And Their Starting Points
23:
We Don't Know Beans About Biotin
23:
Rats and High-Fructose Corn Syrup
22:
Sir James Black, 1924-2010
22:
Benford's Law, Revisited
22:
Ariad Loses on Appeal
22:
The Health Care Bill: A Therapeutic Rant
19:
A Bit More Garage Biotech
19:
The Referee Reports Are In
19:
The Chemical Suppliers: Customer Reviews
18:
Make Your Compound Go Away
18:
Good Suppliers - And The Other Guys
17:
More Blogroll
17:
Dietary Supplements, Charted
17:
Theft at Eli Lilly
17:
BioTime's Cellular Aging Results
17:
Science Buildings: Good, Bad, and Weird
16:
Beta-Amyloid: An Antibiotic?
16:
Terra Incognita
15:
Stem Cell Politics
15:
Tricor's Troubles
12:
Blogroll Update
12:
The PSA Test for Prostate Cancer: Useless
12:
Lilly Layoffs Today?
12:
Garage Biotech
11:
Nonsense About LSD
11:
Intermune's Rise
10:
Vaccines in the Court
10:
How Not to Do It: Liquid Oxygen Cylinders
09:
A GSK/Sirtris Wrap-Up
09:
Hope Darn Well Springs Eternal
08:
Bad News at Exelixis
08:
Not Gonna Make That One
05:
Merck/Schering-Plough People?
05:
Friday Book Recommendation
05:
Twelve and One Half Per Cent
05:
Your Own Personal Bacteria
04:
Dimebon, Grasping at Straws
04:
Mental Health Break: The Alkali Metals Show Their Personalities
04:
Flowing, Not So Gently
03:
Dimebon Comes Crashing to Earth
03:
Fat Rats Make Poor Test Subjects?
02:
AstraZeneca Makes Its Move
02:
Why You Don't Want to Make Death-Star-Sized Drugs
02:
The Plasmid Committee Will See You Now
01:
Blog Traffic - Thanks!
01:
Calorimetry: What Say You?
01:
Layoffs Coming at Eli Lilly?
February 2010
26:
A Friday Book Recommendation
26:
HER2 Confusion
26:
Layoff News
25:
Cranking Away
24:
Knocking on Doors
24:
Steve Nissen's Meeting with GSK
24:
Write A Book, Why Don't You
23:
Things I Won't Work With: Dioxygen Difluoride
22:
Avandia: Off the Market or Not?
22:
The Front Lines of Cancer Treatment
19:
Two For One Sale
18:
Biology By the Numbers
17:
Merck Announces Cuts
17:
Drug Patents in India
16:
XMRV and Chronic Fatigue Syndrome: More Negative Data
16:
Pharma and the Health Care Bill: Value For the Money?
16:
Picking Up Industrial Hires
16:
Twitter and Science, Revisited
12:
Who Follows These Things?
11:
Sanofi-Aventis Cuts Back
11:
Another New Med-Chem Journal
10:
Where Would You Start a Company?
10:
Chemical Supplier Question
09:
More On Pharma's Ugly Finances
08:
Together At Last
08:
Polluting the Literature with PAINs
05:
Sheer Economics: How We Got in This Fix
04:
Here's a Business Plan For You
04:
BMS Freezes Salaries
04:
GSK Day
03:
A Modest Literature Proposal
03:
Dimebon for Alzheimer's: A Black Box Indeed
02:
Literature Notes
02:
A Pile of Malaria Leads For the Taking
01:
And on the Carl Icahn Front. . .
01:
GSK: More Cuts Coming
January 2010
29:
Johnson May Have Been On to Something
29:
Merck and Sirna
29:
Sure Thing
28:
Your First Pharma Bloodletting of 2010: AstraZeneca
28:
A Scorched-Earth Policy at Wyeth's Princeton Site?
28:
Acorda and Ampyra
27:
Enzymes and Fluorines
27:
Sequenom: Strike Up the Music, Bring On the Cream Pies
26:
A Storm in a Teacup
26:
The Infinitely Active Impurity
25:
GSK and Sirtris: A Bit More
22:
Receptors, Moving and Shaking
22:
Maybe You Need Some More Testosterone Over There
21:
An Enzyme Inhibitor You Have Never, Ever, Considered
21:
In Hoc Signo Non Vinces
20:
A Database of Side Effects
20:
Honesty, Of A Sort
19:
What Should Non-Chemists Know About Medicinal Chemistry, Anyway?
18:
Oxford's New Building, One Year Later
18:
Correlations, Lovely Correlations
15:
Physics, for Dogs and Others
15:
Sirtuin Scenarios
14:
Department of Placebo Effects
14:
Gaining and Losing and Discovering and Selling
13:
Two Doses of Crazy
12:
The Sirtris Compounds: Worthless? Really?
11:
Sure About That?
11:
MAGL: A New Cancer Target
08:
Find That Pattern
08:
Reasons Not to Go to Grad School?
08:
Carl Icahn Going For Genzyme?
07:
Is XMRV the Cause of Chronic Fatigue Syndrome? Or Anything?
07:
Extortion, Retractions, And More
06:
Five Technologies For the Scrap Heap?
06:
Lilly's R&D Outsourcing
05:
Always Read the Fine Print
05:
Run It Past the Chemists
04:
Remember Apo-A1 Milano? Pfizer Does.
December 2009
24:
Holiday Time Off
23:
An Alzheimer's Compound Runs Into Big Trouble
22:
GE Healthcare's Idiotic Libel Suit
21:
Faking X-Ray Structures. . .For Fun? Or Profit? Or What?
18:
Day Off!
17:
Why Don't Chemists Communicate? (Or Do We?)
16:
Pass the Popcorn
15:
Manfred Christl Rides Again (Bonus Idiotic Lab Accident, Too)
14:
The Cost of New Drugs
11:
Another Take on the Munos Paper
11:
Munos On Big Companies and Small Ones
10:
Pfizer's R&D Productivity
10:
Selective Scaffolds
09:
Drug Companies Since 1950
09:
Water and Proteins Inside Cells: Sloshing Around, Or Not?
08:
What The Hey? (Abstract Abstracts, Part II)
08:
Another Blogroll Update
08:
Pfizer's Pearl River Layoffs
07:
Why Don't We Have More Protein-Protein Drug Molecules?
07:
Once You Have Paid Him the Danegeld. . .
04:
Caloric Restriction and Lifespan - Without the Caloric Restriction?
03:
All Of You Industrial Scientists: Out Of the Room
02:
Copyright 1671: I Like the Sound of That
02:
Data, Raw and Otherwise
01:
Climategate and Scientific Conduct
November 2009
30:
More Binding Site Weirdness
28:
Recommended Books For Medicinal Chemists, Part One
25:
Light Blogging
24:
Applied Organic Synthesis: Chocolate Pecan Pie
24:
Fear Of Academic Chemistry?
23:
K. C. Nicolaou, Call Your Office
23:
Ozonides As Drugs: What Will They Think of Next?
20:
But These Reagents, Where Are They?
20:
Merck, Shopping in the UK?
19:
What Are the Best Med-Chem Books?
19:
Plavix vs. Effient
18:
More For the Blogroll
18:
I'll Get Right On That For You, Professor
17:
Side Effects, Predicted?
17:
A Blogroll Update
17:
Warren DeLano
16:
Zetia Takes Another Torpedo
13:
Prof. Keith Fagnou
13:
Lumpy Assay Results
12:
Massaging the Data for Neurontin?
11:
Go Spread It On the Rosebushes
11:
Against Panic
11:
Telling the Layoff Story
11:
Pfizer's Chemistry Head Count - Really?
10:
Lab Equipment: Any H-Cube Troubleshooters Out There?
10:
Pfizer's Site Closures - An Analysis
09:
Pfizer's New Layout
09:
So, Do I Own This, Or What? Answer: What
09:
Selling It, And Selling It Hard
06:
Thoughts on What Used to Be Schering-Plough
05:
What Exactly Does Resveratrol Do?
04:
Are You Now, Or Have You Ever Been. . .?
03:
J&J Raises the Ax
03:
That Didn't Take Very Long
02:
In Which You Get to Hear the Phrase "Hatch-Waxman" Again
October 2009
30:
Fifty Years of Scientific History For You
29:
The Best Ones Aren't Over Here Any More?
29:
Four Med-Chem Questions
28:
Nanotech Armor
28:
You Mean You Don't Have to Buy Them?
27:
Reduce Your Number of Reductions, Why Don't You?
26:
Elements I Have Yet to Use
23:
Things I Won't Work With: Straight Dimethyl Zinc
22:
Red Flags in Biotech
21:
"Back to School"
21:
Pfizer's People
21:
O Brave New World! That Has Such Companies In't!
20:
What Pfizer Will Look Like in a Year
19:
Short Topics From All Over
16:
"Day One" at Pfizer
16:
Engineering Receptors: Not Quite There Yet. Not Exactly.
15:
Fall From Grace
14:
Consultants
13:
Those Zanies at Angewandte Chemie
13:
Chronic Fatigue - Retroviruses to Blame, or Not?
12:
Day Off
09:
I'll See Your Conflicts, and Raise You?
08:
Hoist, Petard, Etc.
08:
Retire These Reactions!
07:
A Nobel for Ribosome Structure
06:
Traveling, Updates Later
05:
A Nobel for Telomerase
02:
Placebos Can Work the Other Way, Too
01:
Traffic Record
01:
How To Get Useful Data Out of a Drug Patent
September 2009
30:
Ignoring Patents?
30:
Microwaves Aren't Magic
29:
Nobel Season 2009
28:
Which Pfizer / Wyeth Sites Will Close?
28:
Chew On This, Enzyme
25:
The Details of the Baucus Bill
25:
Faked Data at the ETH
24:
The Grant Application Treadmill
24:
Obesity: Hope Springs Eternal (Summer 2009 Version)
23:
PNAS Shuts a Door
23:
Pay Them Now, Or Pay For It Later
22:
Statin Safety?
22:
Colorful Junk
21:
More on T2, and Degrees
18:
175 Times. And Then the Catastrophe.
17:
The Drug Business: A Turbulent Future?
16:
Real Electrons
15:
Lilly Shrinks
15:
Industrial Research: More Grounded in Reality, or Not?
14:
Abstract Abstracts
14:
Norman Borlaug
11:
Antioxidants and Cancer: Backwards?
10:
To What End?
09:
"Scratch and Sniff" Turns Into "Zap and React"
08:
Right Where You Want Them
04:
Pharma Whistleblowing: How It Works
04:
Sepracor: A Desirable Property?
03:
Real Molecules
03:
A 2.3 Billion Dollar Attention-Getter
02:
Lexapro, Forest Labs, and the Hard Sell
01:
Another Iron Reaction Hits The Mat
01:
Back
August 2009
28:
REACH for the Sky!
27:
Rings of the Future!
26:
Thalidomide for Myeloma: Whose Idea Was It?
26:
Ariad's Patent Rises From the Grave to Smite the Living
25:
Polymorphs and Salts: India Raises an Eyebrow
24:
Arzoxifene: Not the Road to Big Profits?
21:
Obesity Shows Up in the Death Rate? Right?
20:
Still Semaphoring, Even From the Bottom of the Swimming Pool
19:
Time to Sing the Alma Mater
19:
Drug Companies Are Polar Bears? Maybe Not.
19:
The PhRMA Deal
18:
H-h-h-holy C-c-c-c-cow
18:
Schematic Notation for Biology?
17:
PhRMA's Negotiating Game
14:
Spray-Painted For Success
13:
Animal Testing: A View From the Labs
12:
Sulfoxides: A Sneaking Affection
11:
Dealing With Hedgehog Screening Results
11:
Animal Rights, You Say?
10:
Blogroll Update
10:
Pharma's Return on Investment: Yikes
07:
How A Real Drug Industry Project Meeting Goes
06:
Ghostwriting
05:
Just Give It to NIH
05:
How Not To Do It: The Secret Patent Decoder Ring
04:
Wasted Money, Wasted Time?
03:
Savient Feels The Pains of Gout
July 2009
31:
Where Drugs Come From, and How. Once More, With A Roll of the Eyes
30:
Health Care Reform - Really?
29:
Return From Travel: A Note About Cheaptickets.com
27:
Travel Continues. . .
22:
Travel
20:
Amyloid in Trouble
20:
Everything In Its Place
17:
Drug Approvals, Natural And Unnatural
16:
The Further In You Go, The Bigger It Gets
15:
Why Does Screening Work At All? (Free Business Proposal Included!)
14:
RUR
13:
Incompetence, Avoided?
10:
Iran: Politics and Technology Update
10:
mTOR, Rapamycin, and Lifespan: A Startling Study
09:
Too Many Scientists?
08:
How Much Does the Drug Industry Spend on Marketing?
07:
What's So Special About Ribose?
07:
Another Thing We Don't Know
06:
Argumentum ad Crumenam
06:
Farewell to Hard Copies
03:
Day Off
02:
Jargon Will Save Us All
01:
Blogroll Update
01:
Vanda Comes Back From the Dead
June 2009
30:
Voluntary, You Say?
30:
Devils, Metals, and Details
29:
Eli Lilly Gives It Away
26:
Snort Yourself Some Zinc. Or Maybe Not.
25:
What's With Those People at Elsevier, Anyway?
24:
Meanwhile, Over At Sanofi-Aventis. . .
24:
GSK's Getting Better. Just Ask the CEO.
23:
Proxy Server Update
23:
Medarex, Ipilimumab, Prostate Cancer, And Reality
23:
One. . .Billion. . .Dollars!
22:
Funky Carbocycles
22:
Genzyme's Virus Problems
19:
Proxies and Politics Again
19:
More Hot Air From Me on Screening
18:
Professors Patent Pathways and Possibly Profit? Please.
17:
Politics: Proxy Servers Revisited
17:
The View From Pfizer's Corner Offices
16:
Proxies for Iran (More Politics - Mixed With Technology)
15:
Ugliness Defined
15:
Don't Make Them in the First Place?
14:
And Now Some Politics
12:
Selling Zyprexa
12:
Another Sack of Raving Nonsense Is Slated For Publication
11:
Things I Won't Work WIth: Thioacetone
10:
Word For Word - But Why?
10:
Random Questions, Answered Randomly
09:
Instant Med-Chem Wisdom
09:
Avastin's Numbers
08:
Quick Blogroll Update
08:
Rolofylline Hits the Skids
05:
Live-Blogging A Conference: Trouble?
05:
Blog Contestification
04:
Perpetual Patents: A Nasty Thought Occurs
04:
CafePharma Will Now Approach The Bench
04:
Perpetual Patent Motion Machine
03:
Will The Gentleman With the Pitchfork Please Speak Up?
03:
Random Questions
02:
Blog Contestiness
02:
A Deuterium Deal
01:
Akt and Mek, But Not PDQ
May 2009
29:
Ever Have One of Those Days?
29:
Brief Items: Chem Wiki, Autism/Vaccines, Solar Cells
29:
Wait For It. . .Wait For It. . .
28:
Deuterated Drugs: The PTO Says OK, So Far
28:
A Science Writing Award
27:
Homeopathic Merchants Take Your Questions! Well, Sort Of.
27:
Surfin' On The Surface
26:
On the Uselessness of the MSDS
22:
Blowups Happen
22:
Arena, Lorcaserin, and the FDA
21:
J&J Lowers the Boom
21:
The NIH Takes the Plunge
20:
Mipomersen - It Still Works
20:
But You Can't Make Them Take It?
19:
Want To Screen Pfizer's Compounds? Sign Here.
19:
TMS Reagents: Handle With Care!
18:
Arena / Lorcaserin Update
18:
San Francisco Biotech: Holding Up, or Not?
15:
Competing (And Competing Unethically?)
14:
TMS Diazomethane: Update On a Fatality
14:
Surrogate Markers Are Awful, But They're Ours
14:
Goldman Sachs: Out Of the Drug Funding Business Already?
13:
Takeda Evaluating Scientists on "Quality"?
13:
Exercise and Vitamins: Now, Wait A Minute. . .
12:
Book Review Department
12:
Kumbaya
11:
Still More Blogroll Additions
11:
Merck, Elsevier, and Fakery
08:
Blogroll Update
08:
Altermune - Real Stuff or Not?
07:
Angiogenesis Inhibitors: Helping or Hurting?
06:
Into the Clinic. And Right Back Out.
05:
Farewell to ACAT, and to Lots of Time and Money, Too
04:
Writing With Triazoles
01:
Genentech: Let's Hope He's Right
01:
Niacin, No Longer Red-Faced?
April 2009
30:
Faking It on Facebook
30:
Dendreon's Stock: What the Hey?
29:
No MAGIC Involved
28:
Dear Dr. Derek. . .
27:
Don't Hit The Bunkers Just Yet
20:
More Travel!
17:
Genes to Diseases: Hard Work, You Say?
16:
Your Paper (That Sack of Raving Nonsense) Has Been Accepted!
16:
Deuterated Drugs: A Side Effect Already?
15:
Sheesh
15:
Roche Starts to Manage Things
14:
Dendreon's Revenge?
14:
Who They?
13:
An HIV Drug. Or A Gout Drug? Or Both. . .
09:
Ariad's Patent: Let Us Now Dance In Circles
08:
Pfizer's New Structure: Good Luck To All
07:
Biogen Idec: What's Going On?
07:
Scientists Running Your Drug Company?
06:
San Diego
06:
Travel
03:
The Mechanical Chemist?
02:
The Polypill Rides Again
01:
Sponsor A Gene?
01:
Mexican Lemons To the Rescue
March 2009
31:
A DPP-IV Compound Makes It Through
31:
Another Obesity Drug? Not Likely.
30:
Lilly's Latest Loses (This Time)
27:
Layoffs At Merck
26:
Fan Mail
26:
The Motions of a Protein
25:
Two! Two! Two Drugs in One!
24:
Grabbing Onto A Protein's Surface
23:
And While We're Talking About Industry-Sponsored Studies. . .
23:
(Don't) Trust And (Don't) Verify
22:
Blogs and Journalism
20:
What Results Did You Have In Mind?
20:
Drug Industry Research: Reliable or Not?
19:
Fraud: How, and Why, and How Again
18:
Things I Won't Work With: Chalcogen Polyazides
17:
Takeda Gets A Surprise
16:
The Equipment Graveyard
13:
"I’d Like to Structure This Transaction So That My Lunch Buys Me"
13:
And That Is That
13:
Drugs For Bacteria: Really That Hard, Or Not?
12:
Greedy Biotechs?
12:
Roche / Genentech: The Chase Is Over
11:
A Quick Quiz (Re: Antibacterials)
11:
Bacteria: Respect Must Be Paid
10:
Don't Like It? Well, Just Don't Cite It!
10:
Merck/Schering-Plough: Waiting for J&J To Raise Their Hand
09:
The Merck Deal and the SEC: Not a Joke
09:
Merck Actually Does It
06:
Tie Me Molecule Down, Sport
05:
More on Wyeth v. Levine and Preemption
05:
Your Temperamental Diva Reactions
04:
Wyeth v. Levine: Pre-emption Goes Away
04:
Gene Expression: You Haven't Been Thinking Big Enough?
03:
How Good (or Bad?) Are Patent Procedures, Anyway?
02:
Hot Chemistry, Low Tech to High
February 2009
27:
Your Paper Is A Sack Of Raving Nonsense. Thank You.
26:
Ranbaxy in Trouble
26:
Does Glucophage Make Alzheimer's Worse?
25:
Single, Simple Numbers: Use At Your Own Risk
25:
Inspiration Is Where You Find It
24:
Structure-Activity: Lather, Rinse, and Repeat
23:
The Limits of Free Scientist Chow?
23:
Genentech's Culture: At Risk or Not?
20:
Hexacyclinol - Another Request
19:
Hexacyclinol: A Forensic Case
18:
Business Books: The Enantiomers
18:
Supplies of Suppliers
17:
Heavy Atoms, Heavy Profits?
16:
Day Off
13:
A Cure for the Common Cold? Don't. . .Ah, Hold Your Breath
12:
Want A Hard Disease Target? Try Lupus
12:
Autism and Vaccines: Boiling Over Yet Again
11:
A Med-Chem Book Recommendation
11:
Kinases: Hot or Not?
10:
Do Scientists Read Business Books? (Plus: Add a Circle to Dante's Inferno!)
10:
Roche / Genentech: So There is a Deadline
09:
Maribavir, Ouch
09:
We Won't Stay Off The Radar Screen For Long, Y'Know
09:
How Long Is Roche Prepared to Wait?
06:
Short Business Notes: AstraZeneca, Biogen, Vertex
06:
Prep TLC: The Good Old Days Live On
05:
Short Business Note: GSK's At Least Not Going to Merge
05:
Sir James Black Vents, Therapeutically
04:
Fancy Building, Fancy Science?
03:
Their Crime? Collaborating With Other Scientists. . .
03:
The Original Nanotechnology
02:
Short Business Notes: Roche/Genentech, Sanofi-Aventis, GSK
02:
Open Pharma?
January 2009
30:
Roche Goes Hostile - Or Does It?
30:
10,000 Hours To Drug Discovery?
29:
"I Will Cherish the Personally Autographed Book Forever. . ."
29:
Opportunity Costs
28:
Science and Its Values
27:
Pfizer and the Credit Crunch
27:
A Long Tail Indeed
26:
Pfizer / Wyeth: Different This Time?
23:
The Real Hazards of the Lab
23:
Pfizer / Wyeth: They're Going to Take Us All Down With Them
22:
The Great Acetonitrile Shortage
21:
Nitromed: Someone Wants Them
21:
The Hideous Numbers of Compounds
20:
Diversity-Oriented Synthesis: Oriented The Right Way?
19:
Ten Years After: The Genomics Frenzy
16:
Short Items: Viral NMR, Alarming Rings, Cheap Reading, Etc.
16:
With A Straight Face, Yet
15:
The Blogroll
15:
Lilly Pays the Price
14:
Qi Gong and Placebo Effects
13:
More on Pfizer's Layoffs
13:
Lack of Experience, You Know
12:
An Alternative Prescription From Chopra, Roy, and Weil
09:
Poor Equipment Revisited
09:
The Perils of Poor Equipment
08:
Short Items: India, Sanjay Gupta, Satori Pharmaceuticals
07:
Things I Won't Work With: Azidotetrazolate Salts
07:
New Chemistry
06:
Why Pfizer?
06:
Pharmalot Is No More
05:
Well, Hose Me Down. . .
05:
New Year - I Hope!
December 2008
23:
Holiday Break
22:
Publish Your Work The Easy Way
19:
My Compound Goes Where the Wild Goose Goes
18:
When Placebos Were All There Were
17:
Awkward Conversations
16:
Layoffs. More Layoffs.
15:
Insider Trading in Drug Stocks? Not Unknown. . .
12:
The Worst Biotech CEO?
11:
Pfizer's Restructuring Grinds Along
10:
Floppiness Is Not Your Friend: Who Knew?
09:
Goldman Sachs: A New Drug Research Model?
08:
Enhancing the Brain: Here We Go
05:
Squinting At The Pictures, The Modern Way
04:
Curse Of the Lost Compounds
03:
Roche Stalls For Time
02:
Torcetrapib: What Was the Problem? And Does It Matter?
01:
Prodrugs: How the Pros Do It?
November 2008
26:
How Slow is Research Today? Here's a Recipe!
25:
Avandia: Trouble, Run Head to Head
24:
Two Drugs in One? Maybe Not.
21:
The Back Door to the Stock Market
20:
Noisy Numbers
19:
Novartis and Reality
18:
Cheese Dip and Hydrochloric Acid
17:
Liable For Generics? You Are Now!
14:
Sticking It to Proteins
13:
The Yield Monster - And Its Friend, The Model Monster
12:
Crestor: Would It Save Any Lives?
11:
Wash Your Tubes; Mess Up Your Data
10:
Crestor: Risks Up, Risks Down
07:
System Biology: Ready, or Not?
06:
CB-1 Obesity Drugs: Farewell to the Whole Lot
05:
We Now Return to Our Regularly Scheduled Program
04:
We Interrupt This Science. . .For Some Politics
03:
Pfizer: Strategy, Layoffs, and Money
October 2008
31:
Fructose In The Brain?
30:
Lilly And Imclone: Not Expensive Enough!
29:
Cutbacks - But Not As Bad This Time
28:
Out the Door and Down the Stairs
27:
Publish And Be Damned, Most Likely
24:
BlackLight Power Responds
23:
Merck Cuts Back (Again)
22:
Blacklight Power: What on Earth?
21:
Things I Won't Work With: Triazadienyl Fluoride
20:
Fearful Symmetry?
17:
Down The Chute in Phase III
16:
Animal Models: How High to Set the Bar?
15:
Where Are the Drugs?
14:
Impact Factors: Can We Pretend That They Don't Exist?
13:
Old School - Really Old
10:
Kevin Trudeau: A Bit of Good News
09:
More Glowing Cells: Chemistry Comes Through Again
08:
A Green Fluorescent Nobel Prize
07:
Nobel Season 2008
06:
Imclone Really Does Get Bought
03:
Day Off
02:
Taranabant Is No More
02:
Eli Lilly and Imclone: Sensible? Real?
01:
Hard Times: A Manifesto
September 2008
30:
Various Drug Industry News, None of It All That Good
29:
Why Don't You Just. . .
26:
Prasugrel Today?
26:
Imclone's Secret Admirer
25:
Pfizer: As We Speak?
25:
Protein Folding: Complexity to Make More Complexity?
24:
Ariad's Patent: A Court Rules
23:
You Call That An X-Ray Source?
22:
More Than This
19:
Sunesis: No Substitutions Allowed?
17:
Sugars: Still Crazy After All These Years
17:
Ranbaxy: Cutting Corners, or Falsely Accused?
16:
Neil Bartlett, 1932-2008
15:
Extracting Money From Matthias Rath, For A Change
12:
BMS vs. Imclone: Godzilla Exchanges Legal Language With Mothra
11:
US and UK Biotech: Growth and Form
10:
Pfizer / Bayer?
09:
Antipsychotics: Do They Work For A Completely Different Reason?
08:
The Complicated Causes of Cancer
05:
Samurai! Unleash Your Drug Candidates!
04:
X-Ray Structures: Handle With Care
03:
Direct To Consumer Ads: Wasted Money?
August 2008
29:
Sticky Containers, Vanishing Drugs
28:
PNAS: Read It, or Not?
27:
Crowded Proteins
26:
New, Improved DNA?
25:
How Not To Do It: Water Aspirators
22:
Open Source Science?
21:
RNAi: Bubble or Not?
20:
Replacing What's Being Lost
19:
Fighting Boredom, Profitably
18:
Genentech and Roche, Act Two
15:
Back
05:
Roche Palo Alto: What's Going On?
05:
Time Off
04:
Job Seekers: Genentech, GSK, and Elsewhere
01:
GSK Layoffs: Yes, Again
July 2008
31:
Rember for Alzheimer's: Methylene Blue's Comeback
30:
Bapineuzumab: Good For Anything or Not?
29:
Iloperidone: A Schizophrenia Drug Goes Down For the Last Time
28:
Questions You Don't Necessarily Want the Answers To . . .
25:
Should Genentech Be a Part of Roche?
24:
Confident
23:
Patents Stopping an Alzheimer's Wonder Drug?
22:
Vytorin: Another Round of Nasty Results
21:
Backtracking, Necessary and Unnecessary
18:
Lowe's Law of Diurnal Distribution
16:
Receptors: Can't Live With 'Em, Can't Understand 'Em
15:
Metabolic Hope Springs Eternal
14:
Things I Won't Work With: Cyanogen Azide
11:
Sharing the Enlightenment
10:
More on Outsourcing
09:
How's The New Boss Doing?
08:
Glaxo Asks the Eurocrats
07:
Pfizer's Prospects: Just Ducky
04:
Happy Fourth of July
03:
I Can Has Ugly Molecules?
02:
More Pfizer Layoffs?
01:
Leaving Comments: A Fix
01:
The Gates Foundation: Dissatisfied With Results?
June 2008
30:
Another Alzheimer's Compound Goes Down
27:
Unknown - But You Can Buy It
26:
Funding in the EU: The Simple Way
25:
(No) Anarchy in the EU: A Report From Inside
24:
Prasugrel: Come Back This Fall
23:
Auroral Activity
19:
Anarchy in the EU
18:
All The Fat Cells You'll Ever Have - Sort Of
17:
Protecting Amyloid's Parent?
16:
Alli: "Underwhelming"
13:
Elan Tries Again
12:
Suits vs. Lab Coats?
11:
More On the GSK Layoffs
10:
GSK: Money-Green Outside, Pink-Slip Inside
09:
An Impressive Nanolist of Nanocitations
06:
Resveratrol in Mice
05:
Merck, Vioxx: Seventeen and Three
04:
Tote That Barge, Lift That Bale
03:
Oops
02:
A Breath of Fresh Air from Fuji
May 2008
30:
Ah, Glassware
29:
Nullius in Verba
28:
Awash in Yen
27:
An Eye For the Numbers
23:
Up Close and Personal
22:
Killing Proteins Wholesale
21:
Lurching Around For Fun and Profit
20:
The Miracle Solvent
19:
Empty As Can Be
16:
Nanotech Stem Cells, Order Now!
15:
Copper: A Gentleman's Disagreement
14:
Summer Student Time
13:
In Which I Hate A Wonder Drug
12:
Explaining It All
08:
Merck Bails on Natural Products
07:
Science By Country
06:
Alzheimer's: A Report From the Front
05:
Naming of Names
02:
"Not Useful" Means "Not Approvable", Right?
01:
O Pioneers!
April 2008
30:
How Not To Do It: Diazomethane
29:
Cordaptive Q and A
28:
A Salute
25:
Why Buy, Anyway?
24:
$720 Million Worth of Sirtuin Research
20:
Quick Note
18:
Cut It Out. Cut It Out Now.
17:
Getting Smarter Already?
16:
Fun With Bacteria
15:
Walk Around Some
14:
Fifteen Minutes Shot
14:
A Meditation on Solvents
11:
Free Sushi in the Cafeteria!
10:
Exubera, Safety, and No Guarantees
09:
And You Thought Exubera Was A Disaster Before
09:
Another Pop Quiz!
08:
Fun With Tunichromes
07:
Pre-emption For Real?
04:
Another Cholesterol Medication Goes Down (Or Does It)?
03:
Whose Guess Is Better?
02:
Vytorin Numbers
01:
Vytorin: It's A Pity
March 2008
31:
Writing It Down
28:
RNA Interference: Even Trickier Than You Thought
27:
Start Small, Start Right
26:
The Lucky Bonus Pack
25:
Getting To Lyrica
24:
That's Never Gonna Work
21:
Pfizer Loses, So Far
20:
Anonymity?
19:
Now Your Liver Doesn't Have to Make It For You
18:
A Solution, Courtesy of the MIT Faculty
17:
You Get What You Pay For?
14:
Pen and Paper
13:
Pfizer vs. the NEJM: A Legal Showdown
12:
Taranabant in Trouble?
10:
Fill Out Your Pharma Brackets
10:
Hits, Misses, and Some More Misses
07:
Dissolve Your Troubles Away
06:
Fakery And Its Ends
05:
Smaller, Wetter, Harder to Work With
04:
Off Target? Which Target Did You Mean?
03:
Big Steaming Heaps of Fraud
February 2008
29:
How Not To Do It: Column Chromatography
28:
ApoE4: Test or Not?
27:
Antidepressants: Depressing News or Not?
26:
Sand Won't Save You This Time
25:
More On Merck and Taranabant
21:
New Tricks With Glassware
20:
What You Become Known For
19:
Day Off
15:
Putting Out the Inevitable Fires
14:
Getting Real With Real Cells
13:
One Time Only. Or Maybe Just a Few.
12:
DNA Forklifts, DNA Pliers
11:
Fast Plaques in a Slow Disease
08:
A Look Under the Hood
07:
Write It Down, Write it Down
06:
Dig the New Breed
05:
Room At The Bottom, For Sure
04:
How Many PPIs Does the World Need?
01:
Commenting Issues
01:
A Few Questions For My Fellow Pharma Chemists
January 2008
31:
Drugs and Money
30:
Recycle, Reuse, Republish
29:
The Animal Testing Hierarchy
28:
Laissez-Faire?
25:
Extractions: A Way of Life
24:
Cheap Happiness
23:
Making the Adjustment to Smallness
22:
These Fragments I Have Shored Against My Ruins
21:
Breaking the Contract of Aging
18:
Eat It, Breath It, Soak in It?
17:
The EU Suspects No One, And Suspects Everyone
16:
Judah Folkman
14:
Vytorin, Holed Under the Waterline
11:
They Can Be Ranked - Somehow
10:
Drugs and Money and How It Feels
09:
Ah, Politics
08:
Rainbows and Fishing Expeditions
06:
Dollar, Drugs, and Advertising
04:
Plants For Cancer?
03:
Top of the Heap
02:
Back On the Air
December 2007
21:
Winterize Your Ideas
20:
Snow Day
19:
Scrape Off Some Attitude
18:
Hearing Footsteps
17:
Le Dernier Cri
14:
Biogen's Not For Buying. For Now.
13:
Underperforming Triple Bonds
12:
Med-Chem Layoffs, On the Front Page
11:
A Bad Assay: Better Than None?
10:
More Belts Tighten
07:
Kids These Days!
05:
Avandia: Going Under for the Third Time?
05:
Unacceptable
03:
The Big and the Little
03:
Exciting Nonsense Wins Another One
November 2007
29:
Neat! Wish It Were True!
28:
Bad Luck For Novartis - And For Diabetics
27:
Then I Felt Like Some Watcher of the Skies. . .
26:
Still and All
25:
You Do The Easy Stuff; I'll Do the Easier
21:
Synthetic Prep of the Day: Chocolate Pecan Pie
21:
Holiday Break
20:
And It Goes Like This!
19:
Depressing Figures for Acomplia
15:
Quiz Time!
15:
And Speaking of Discovering Things. . .
15:
Maybe Not Improved, But Definitely New
14:
How You Doin'? How's Everybody Doin'?
12:
Here Be Chiral Dragons, With Fluorinated Fangs
11:
A Real Genetic Headscratcher
09:
One Year
08:
Dumber in English?
07:
Reasons to Be Different
06:
Lights, Camera, Pharma!
06:
Andy Grove: Rich, Famous, Smart and Wrong
05:
Bright Lights and Applause?
04:
Nerve, Lots and Lots of Nerve
02:
One For the Brave
October 2007
31:
Resistant Little Creatures
31:
How Not to Do It: Hydrogen Bromide
29:
What We Don't Know About Enzymes
29:
Bacterial Infection: Better Or Worse Than Cancer?
25:
Looking Backwards
24:
Come On. Improve, Already.
23:
Vial Thirty-Three, And More
22:
Surveying the Exubera Crater
18:
Understanding Dawns
17:
Biogen on the Block?
16:
Three Things You Need
15:
Checking The Numbers on the Alzheimer's Test
15:
Enzyme Humility
12:
Unnatural, And Proud Of It
11:
Let Us Now Turn To the Example of Yo' Mama
10:
Ertl Wins: Down With Witchcraft
09:
Nobel Chemistry Odds
09:
Blogroll Update
08:
Nobel Season
04:
No Problem At All
03:
More Layoffs, And What They Might Mean
02:
Why Now, And Not Before?
01:
All Sorts of Holes
September 2007
30:
If Not This, What?
27:
Thimerosal. Again.
26:
Expensive Reading
25:
Hey, Graduates! Negotiate Hard, You Hear, Now?
24:
More Sirtuins With More Effects
24:
Good News From the HR Department!
20:
Go With The Er, Flow?
19:
Fixing the Patent System?
19:
The Good Old CombiChem Days
18:
Ugly, But Useful
17:
Arsenic, Patents, and the World
13:
Don't Step Over It, Even If It's Right in Front of You
12:
Drugs From Where?
11:
Fresh Air, Or What Passes For It
10:
Have We Got A Deal For You!
09:
Guess That Market
06:
Aromatherapy
06:
More Things Than Are Dreamt Of
02:
Renin, Wherefore Art Thou, Renin?
August 2007
31:
Here It Goes
30:
Elbow Room
28:
Like Clockwork
27:
Oh, Come On
26:
Cheer Up
23:
". . . Jobs That Don't Exist"
21:
Sorting Through the Piles
21:
Ah, Rumors
20:
The Current Cancer Long-Jump Record
17:
More on Interview Seminars
14:
Winning, By Tying Losers Together
13:
Pilferage
12:
These You Shall Have Always With You
09:
Buying What You Can't Make? Or What?
08:
Steve Ley, Azadirachtin, and Me (Very Much in That Order)
08:
Exubera Spirals Toward the Drainpipe
07:
Meet the Blogger?
06:
Here, Fix This, Would You?
05:
The Choir Hears It Again
03:
Not Necessarily So
01:
Run! Anthropologists!
July 2007
31:
Incomprehension, Out For A Stroll
30:
Avandia's Latest Round
27:
You Discover It, We Sell It. Deal?
25:
From the Sequencer to the Drugstore?
24:
Godzilla vs. Mothra? Relman vs. Epstein!
23:
Deactivation, After All
22:
A Farewell to Tin
19:
Hype In Spaaaace!
18:
Over There, Behind That Stack of Whatchamacallits
17:
Visfatin: Real Or Not?
16:
European Drugs, American Drugs
15:
Proteomics 101
13:
Pour Encourager Les Autres
11:
First Impressions
10:
Travels In Numerica Deserta
09:
Now With Ethyl Mesylate!
08:
Starting Up Again
June 2007
26:
Two Weeks Off
21:
Real Life, Which Costs Real Money
20:
Bigger, Tougher, Longer? Or Not?
18:
Right Down the Alli
17:
Access To Science
15:
Rimonabant: Down to Earth
11:
Rimonabant, Out In the Light
07:
The Chamber of DNA Secrets
06:
Massachusetts Moving
06:
A Post I've Been Looking Forward to For Months
04:
Phase Zero?
03:
Pecunia Non Olet?
May 2007
31:
The Avandia Wars Continue
29:
Knowing What You Know. . .
25:
More Avandia, And More on Marketing
24:
Avandia: Trouble or Not?
23:
Exalted Paper
22:
Evolution In Action
20:
Little, Big
18:
But Enough About You
17:
Beta-Secretase: Not So Fast?
16:
Sunbeams, Single Electrons, and You
15:
Into The Trackless Wilderness
14:
Safer Every Day!
10:
Alas, Dendreon
09:
A New FDA?
09:
Blogroll Update
07:
Nonsense. On Stilts. Playing a Trumpet.
07:
Brazil Raises The Pirate Flag
03:
Forewarned is Forearmed
02:
Obvious Ain't Obvious No More
April 2007
30:
Outsourcing Blues?
29:
Time To Conduct Some Business
26:
Less Than Zero
25:
A New HIV Therapy. Yawn?
24:
Put Your Money Down
22:
Melting Keys and Squishy Locks
20:
Worst Animal Model: Nominations Are Open
19:
Let A Thousand Flowers Bloom
19:
The Big Time
18:
Cro-MagnonDraw
17:
The Doctorate and Its Discontents
15:
Doctorate or Not?
13:
Deep Breaths
12:
Layoffs - Again
11:
Exubera: This Time With Feeling
11:
Amgen: The Pythian Oracle Laughs Again
10:
Sulfur, Your Pal. Mostly.
08:
Buy! Sell! Shout! Moan!
05:
Awful, No Doubt. But Not As Awful as Before?
04:
Linkage!
03:
Vaccines Everywhere
02:
Failure: Not Your Friend, But Definitely Your Companion
01:
The HDL Compost Pile
March 2007
30:
Rimonabant, Slowly
29:
I Want A New Nitro
27:
ACS Meetings
26:
Vectibix Lurches A Bit
25:
Wandering Through the Hydrides
23:
Naked Synthesis
22:
FDA Advisory Panels: Pay, No Play
20:
AGI-1067: Dead or Alive?
19:
Scientists, All Over
15:
Lousy Reactions: Reader's Choice
14:
Schering-Plough Goes Shopping
12:
No Shortcuts
11:
More Help Wanted?
08:
How Not to Do It: More Diethyl Ether (Now With Extra Hardware)
07:
Fish Nor Fowl?
07:
Quietly Disappearing From the Skies
06:
Decisions, Decisions
04:
Calcium: A Backwater
01:
How Not to Do It: Tertiary Butyllithium
February 2007
28:
Have We Got a Job For You!
27:
Wrong, But Still Convincing
26:
Hedgehogs in Stockholm
25:
Biotech's Net Loss?
23:
F. A. Cotton, 1930-2007
22:
Inspirational Reading?
22:
Back From DC
21:
CMPI Conference: Critical Path
21:
CMPI Conference: CATIE and ALLHAT
21:
CMPI Conference: Lunch With the FDA
21:
CMPI Conference: Panel on the Politics of Drug Evaluation
21:
CMPI Conference: Panel on Media Coverage
20:
Something From Nothing
19:
You Want Me to Just Talk? No Problem.
18:
Wake Up and Smell the Solvents
16:
Comments on Comments
14:
Gene Patents, Part One: Genes As Chemicals
13:
Crichton, Patents, and Genes
12:
A Good Day's Work
12:
Good Sense Breaks Out, Film at Eleven?
08:
Depraved and Deprived
07:
There's Toxicity and There's Toxicity
07:
Vertex, Hepatitis, and Gripping the Arms of Your Chair
05:
Good Mistakes?
05:
A Break, Whether I Felt Like It Or Not
04:
Going Hollywood, For Our Own Good?
01:
How Not To Do It: Ruining Stuff
January 2007
30:
BMY-SNY?
29:
Open For Business
29:
Blogroll Update
28:
What Can Academia Do?
25:
The Big Picture
25:
Way Out Here
24:
Back on the Air
17:
Pfizer's Pfinances
16:
How Not to Do It: Sophomore Organic Edition
15:
Novo Nordisk Axes Med-Chem
14:
Problems and Solutions
12:
Ghost Town
11:
An Innocent Question
10:
Upside Down Activity
10:
Reality, Here In This Little Dish
09:
That Smell
08:
PLoS One
07:
Good Stuff and Bad Stuff
04:
Take Your Shots (For Real, This Time?)
03:
You'll Be Safe Under Here. Maybe.
02:
That Can't Be Right - Try Again
02:
And The Winner Is. . .
02:
Out With the Old
December 2006
28:
Cleans Down to What Should Be the Shine
26:
Work At Home! It's Easy; It's Fun!
21:
Holiday Schedule
20:
Injustice
19:
Hi, My Name Is [...]
18:
ICOS In Pieces?
14:
Love and Anger
13:
Ars Longa, But Instructions to Authors Say "Brevis"
11:
Torcetrapib: The Foil-Lined Hat Perspective
11:
Old School? Same School!
08:
Shameless Self-Promotion
07:
Are You Experienced?
06:
Bigger And Greasier
04:
Too Near the Sun?
03:
The Torcetrapib Catastrophe
01:
Pfizer's Sizing
November 2006
30:
The Other Side of the Table
29:
Bad Interviews
27:
The Litvinenko Case: More On Polonium and Alpha Particles
27:
Polonium Poisoning
21:
The Paper Mountain
20:
Sell! (It's Not Just Me)
17:
Ah, the Heck With the Error Bars
15:
Vial Thirty-Three: Warp Drive
14:
Where Do All The Chemicals Go?
14:
Elsewhere
13:
The Race Is On
10:
Publish, Then Perish
09:
Help Wanted - I Hope
08:
Watch This Space
08:
Links and Such
06:
It Went Up Instead of Down
06:
Chinese Med-Chem - In China, For Once
02:
Hope, Springing Eternal And All That
01:
And Thee, O Time
01:
You Can't Make Money If You Don't Get Paid
October 2006
30:
Blow The Trumpets
29:
Family Portraits
26:
It Should Work. It Just Doesn't.
25:
Mass Spec on Mars
24:
Naming of Names
23:
Experimental Compound Codes
22:
The Unattractive Truth
19:
Levoglucosan
18:
Peptides as Texts
17:
Up Periscope And Fire All Bow Tubes
16:
Show What You Know
15:
German, Anyone?
12:
More Handedness
11:
On The Other Hand
10:
Five Things I Haven't Used in Years
09:
Forty NMR Magnets and 3000 Proteins Later. . .
09:
Here and There
05:
The Inscrutable French
04:
Cheer Up, You Chemists
04:
Another Chemistry Prize for Biology
03:
Neuropeptide Y Dies, But It Never Surrenders
02:
RNA Interference: Film at Eleven
02:
Nobel Update: RNAi Wins
01:
Test Your Skills!
September 2006
28:
The Horse Latitudes
27:
Nobel Fever Is Upon Us
26:
Smell the Vibrations
25:
A Spray-Painted Crystal Ball
24:
Touch Me Not
22:
Darn Photons
20:
Imclone, Drama Queen of Biotech
19:
By Any Other Name
18:
Tenderbutton Calls It Quits
17:
Tough Targets
14:
Take Your Shots
13:
Spectroscopic Days
12:
Walking the Plank at Bristol-Myers Squibb
11:
Enzymes Do Whatever They Want To
10:
If You Want Your Explanations Overnight, It'll Cost You
07:
Inherently Obvious - It's Obviously Inherent
07:
Move On, Move On - Nothing To See Here. . .
06:
Tell 'Em You Work On Something Else
05:
Ariad's Patent Eviscerated
04:
Plavix Plot Twists
01:
Merck: Unfigure-outable
August 2006
30:
Those Darn Invisible Creatures
29:
Evil Thoughts of Evil Things
28:
Paper on a Shelf
27:
Floyd Landis: Could His Cortisone Treatments Exonerate Him?
24:
Respect! Honor! Recognition! All For $149.95!
22:
Explain This, Hot Shot!
15:
Kevin Trudeau Was Born in 1963
15:
Here and There
14:
Tegenero, In Detail
13:
Six Chem-Geek Questions
10:
The Great Plavix Disaster
10:
Airplanes and Chemicals
09:
Ray Kurzweil's Future
08:
Back in Court With Ariad and Lilly
07:
A Vaccine Against Putting on Weight?
06:
Where Do They Come From?
03:
The Last Word on Eerie Glowing Labs
02:
A Law of the Lab: Yields and Variations
01:
Testosterone, Carbon Isotopes, and Floyd Landis
July 2006
31:
Hobson's Choice
30:
Pfizer's Man at the Top
27:
Good News, Now That I Think About It!
26:
Pfizer Recalculates
25:
The Sun Shines at Pfizer
25:
Back To Life
23:
Hexacyclinol Rides Again
20:
Peptide Craziness
19:
Fuzeon's Fallout
18:
Getting and Spending
17:
Pounding Sand
16:
The Future is Unwritten
13:
A Friday Linkfest
13:
J&J Shrinks Their Labs Again
11:
More Purple Radiance
10:
Aluminum: Friend or Foe?
09:
Down the Chute: Your Call
07:
Memo to the Public Relations Department
05:
More Statin Skirmishing
04:
Now With the Great Taste of Fish!
03:
Pyrotechnic Days
June 2006
29:
Rimonabant Arrives
28:
Part Nine Hundred and Forty Two in a Series. . .
27:
Academia in Summertime
26:
Vioxx: 18 Months to Trouble?
25:
Neurocrine's Choice
22:
To The Third Darn Decimal Place
21:
Waste O' Time Awards
20:
Formally Undecideable
19:
Rats Rule, Right?
18:
More on Voodoo
15:
And 0.04 Molar in Eye of Newt. . .
14:
Vox Populi
13:
The Fur Continues to Fly
13:
Disapproval of Approvability
11:
What's German For "Food Fight"?
11:
Vial Thirty-Three: The Third Run
08:
Peter Kim, So Far
07:
Best When Used By. . .
06:
Vial Thirty-Three Rides Again
06:
Vial Thirty-Three: One Up, One Down
05:
Hexacyclinol? Or Not?
04:
Resistance Isn't Quite Futile
02:
Brief Political Interlude
01:
That Fount of Information We Call ASCO
May 2006
31:
As Merck Caroms Off Another Tree
30:
Things I Won't Work With: Frisky Perchlorates
29:
Ask Not
25:
Too Big to Discover Anything
25:
Back on the Air
23:
Can't Buy These Thrills
22:
Merck and the Numbers
22:
Mid-day Update
21:
Chem-Geek Alternate History
20:
Minute by Minute
18:
A Question For the Crowd
18:
Vial Number Thirty-Three
17:
Merck's Latest Underwhelming Data
16:
The New England Journal And Its PR Flacks
15:
Leadership Secrets of the Data Fudgers
14:
Cliff Diving
11:
A Day at the Rota-Vap
10:
A New Route to Tamiflu?
09:
Ends, Means, Rats, and Dogs
08:
A Natural Wonder Drug - Now What?
07:
Yet Another Law
04:
Ariad Wins a Round
03:
Access to Phase I Drugs: A Constitutional Right?
03:
Full Disclosure
03:
Have The Rules Changed?
02:
Things I'm Glad I Don't Do: Isolating Ciguatoxin
02:
Travel
April 2006
30:
All Natural
27:
Golden Parachute, Still Packed and Ready
26:
Jungle Rot
25:
A Shot Across the Bow
24:
Merck, So Far
23:
You Can't Win If You Don't Play
20:
Sulfurous Stenches: A Connisseur's Guide
19:
Why All the Gloom?
18:
There Is a Tide. . .
17:
Reading Our Own Press Releases
16:
Don't Know. Don't Care?
12:
The Process of Process
11:
Ariad's Day in Court
10:
Linkorama
09:
New Frontiers in Self-Deception
06:
How Not to Do It: Distilling HMPA
05:
Which World Do We Live In, Anyway?
04:
Once More Into the Patent Breech
03:
More On Doing Away With Patents
02:
Down With Patents, Eh?
March 2006
30:
Give The People What They Want
30:
Missed One!
28:
Rioting for Unemployment
27:
Cleaning Out the Hood: An Internal Monologue
26:
A Word to the Wise About TGN1412
24:
Explosion News
24:
Can You Say "Uebernahmeangebot"?
23:
Crystals of Doubt
22:
A Lengthy Day
21:
Nitromed's Slow Decline
20:
Grad School, Blogged
20:
TNG1412: Was There a Warning?
17:
Update on TGN1412
16:
Price Gouging or Not?
15:
No Immunity From Immunity
14:
Neowater Replies
13:
The Big Statin Pillow Fight
12:
Bubble Fusion Implodes
09:
Wonder Drug, Indeed
09:
Men and Women and Science and Jobs
08:
How Not to Do It: Liquid Nitrogen Tanks
08:
Things Turn Nasty
06:
Man Hands on Misery to Man
05:
Journal of Biological Chemical Biochemical Chemical Biology
02:
Technical Difficulties
02:
Procter and Gamble Throws in the Towel
01:
Deception Begins at Home
February 2006
28:
More on Outsourcing
27:
But At My Back I Always Hear. . .
26:
Tied to the Mast
24:
What's French for "Trust Us"?
23:
Blogroll Revamp
22:
NEJM vs. Its Contributors, Round Two
21:
Gold and Lasers
20:
Rimonabant Bangs Into. . .Something
19:
Because I Never Lie, and I'm Always Right
16:
What's It Worth to You?
15:
Pfizer Takes a Deep Breath
14:
First Slide, Please
13:
Heart-Warming Stories of Success
12:
Kinase Inhibitors: Doomed From the Start?
09:
Ban Intelligent Design?
08:
Garnier Strikes Back
07:
Return of Neowater
06:
J&J Shakes Things Up
05:
Stream of Consciousness
02:
Nanotech Wonder Water?
01:
The Good New Days
January 2006
31:
Here's A Shovel. Could You Dig Yourself In Some More?
30:
Forecast: Rain, Eventually
29:
Name Reactions for One Thousand, Alex
26:
Ah, It's Fine. Just Send the Darn Thing Out Already.
25:
If It's Not One Thing. . .
24:
The Examiner Finally Snaps
23:
Merck versus the New England Journal
22:
Full Disclosure
19:
But His Name Lives On. . .
19:
Tamiflu: Good For Anything, Or Not?
18:
A Scientific Aptitude Test?
17:
Gimme That Old Time Reaction
17:
Dangerous Thoughts
16:
Various Updates
15:
The FDA Loosens Its Tie
13:
How Not to Do It: Ether Peroxides
12:
Plenty of Tar to Go Around
09:
Stem Cell Disaster
08:
My Shopping List
05:
Ugly, But Effective
04:
Mice, Humans, and Cancer
03:
Pemoline Problems
03:
Comments Welcome - Really
02:
A Scientist's Resolutions
December 2005
29:
Outside Reading
27:
What Makes an Ugly Molecule?
23:
Sort Of Like A Wine Cellar
22:
Poor Put-Upon Intelligent Design
21:
Another Shot at Cancer
20:
The Dover Decision Comes Down
20:
Does Celebrex Have A Future At All?
17:
How Not to Do It: Bromine
15:
Attack of the Angry Viruses
14:
An Expensive Way Back for Celebrex
13:
The New England Journal of Legal Immunity?
13:
Grand Rounds
12:
Play by Play in the Lab
09:
A Vioxx Bomb Drops. Or Does It?
07:
The Hard News on Cancer
06:
Well-Rounded?
06:
Grand Rounds Today, and Next Week
05:
Home Sweet Home
04:
Not On the Same Page
02:
The Bell Finally Tolls for Peter Rost
01:
Rigel's Puzzling Failure
November 2005
30:
Okadaic Acid Makes Vanity Fair
30:
Merck Update
29:
Ghrelin and Obestatin
28:
Merck, Finally
27:
Hire the Thoroughbreds?
25:
Instead of Working
22:
Serono's Suitors
21:
Run, Do Not Walk, To The Nearest Exit
21:
Old Standbys
20:
Sir2 Surprise
17:
A Man, A Book, and a Plan. Several Plans.
16:
What Sort of Training?
15:
Statin Showdown
14:
One Darn Miracle After Another
13:
Arcadia's Furnishings
11:
Gene to Drug: You Bet
10:
. . .And That Settles It
09:
Cash For Vaccines
08:
University of Drug Discovery?
07:
Intelligent Design, Molecule By Molecule
06:
The Dover Decision
03:
Merck Off the Mat
02:
The Flu Plan, Part Two: Antiviral Drugs
02:
The Flu Plan, Part One: Vaccines
01:
Molecular Modeling Cage Match
October 2005
31:
Five Questions
30:
Gooooaaaal!
28:
Pargluva Goes Down?
27:
Imclone Revisited
26:
The Latest in Pharmaceutical Technology
25:
Start Your Engines
24:
Hype or Hope?
23:
The Tar Pit Beckons
20:
This Had Better Be Good
19:
Complaints From a Fossil
19:
Procrastination Assistance
18:
Waiting for Pargluva
17:
James Cramer, Biocryst, and You
16:
Matthias Rath, Pioneer
13:
Buy! It's More Expensive Than Usual!
12:
The Undefeated Brazilian Team
11:
The Old Stuff
10:
Time and Chance
09:
Needs and Wants
06:
The Great Divide
06:
Outside Reading, and Plenty of It
05:
Human Genome Science Hits the Wall
05:
Metathesis Nobel!
03:
Where Do the Good Ones Go?
03:
Well Deserved
02:
A Piece of the Action
September 2005
30:
And Another Thing. . .
29:
The Hazards of Molecular Modeling
28:
Clamping Down, or Loosening Up?
27:
Tribes
26:
Antivirals "Gathering Dust"?
25:
Report From What I Think is the Frontier
22:
By a Nose in a Head to Head
21:
No Clear Winners
20:
Say It Again!
19:
Klotho: Sooner Than You Think?
18:
A Sensitive Guy
15:
Pretty Much the Reason You'd Think
15:
Here and There
13:
It Pours on Ligand
12:
". . .And to Furbish Falsehoods For a Magazine"
11:
Remind Me Not to Do This Again
08:
Muraglitazar's Turn
07:
The Tiniest Doors Begin to Open
06:
Ranking the Journals - Try It at Home!
06:
Crossing Your Fingers, Authoritatively
01:
Thought For a Long Weekend
August 2005
31:
More Fun With Impact Factors
30:
Our Friend the Impact Factor
29:
pHooey
29:
Nature Doesn't Care: Latest in a Series
28:
Kevin Trudeau's Snake Oil Empire
25:
The Painful History of Substance P
24:
Having the Hands
23:
Outside Reading
23:
Gritting Our Teeth
22:
Mutual Suspicions
21:
Okay, One More Merck Point
21:
No More Merck For A Couple of Days
19:
Judgement Day
18:
Everything's Under Control, Right?
17:
No Such Disease
16:
For Further Enlightenment
16:
Experimental News
15:
Out the Door and Over the Edge
14:
Blogging About Science Blogging
11:
Selectivity: One of Those Flexible Concepts
10:
Another Thing You'd Think Would Be Simple
09:
Differences Between Academia and Industry, Pt. 4
08:
Room At the Top?
07:
An Off-Topic Ramble
06:
Even More Worthwhile Stuff
04:
The Place to Be
03:
Let's Check This Blank Page, Here
02:
Never Came In Handy. Not Once.
01:
Seven Questions
July 2005
31:
At Your Newsstand Today
28:
Like, Er, Fine Wine. I Hope.
28:
A Tale of Two Trials
27:
Once And For All
26:
Merck on Trial
25:
Hydrogenation Made Easy?
25:
The Check Shows Up in the Mail. Really.
21:
Science Marches On
20:
Arr, Me Hearties!
19:
Sitting Through Some Chemistry
18:
The Leash of the Law
17:
And It Goes Like This
09:
Summer Hours
07:
More on Brazil and Kaletra
06:
Brazil Pulls Out the Pin
05:
Dinner the Night Before
05:
Continued Slacking
03:
Happy Fourth of July
June 2005
30:
Where's the Combo?
29:
Vaccines and Human Folly
28:
Cancer Delusions
27:
Thimerosal, Again
26:
How Not to Do It: Vacuum Pumps
23:
News Flash: I May Not Be a Fool
22:
Fan Mail
21:
Morphine in the Brain: Go For It, or Not?
21:
Data, At Last
20:
More Brain Surprises
19:
What Makes A Target, Anyway?
16:
Pfizer Opens Their Wallet - Again
15:
How Safe Is This Stuff?
14:
Fungal Problems
14:
The Research Exemption Lives!
12:
How Not to Do It: Distilling Benzene
09:
Dr. Rath Does What He Can
08:
A Day in the Life of Peter Rost
07:
Experimental Update
07:
When the Alternative is Nothing
06:
A Drug's Target, Finally
05:
Biotech At Last, Eh?
02:
How Much Success?
01:
As Thin As a Soap Bubble
May 2005
31:
Modeling the Modelers
30:
Tailfins and All
27:
Compounds for the Sake of Compounds
25:
The Voice of Experience
24:
You Figure It Out
23:
Intelligent Chemical Design
22:
That Has to Be Good, Right?
20:
Outside Reading
18:
Vertex Turns Over a Winner
17:
Very Wrong, or Very Right
16:
Days of Silicon and Roses
16:
Cuprate Voodoo
13:
ASCO Fever
11:
Public Utility, You Say?
10:
Getting Hired as a PhD
09:
Punching the Clock at Merck
08:
How To Get Hired: Associate Positions
06:
'Tis the Season
04:
Another Law of the Lab
03:
Ghostly Influences
02:
Merck and Integra Go the Distance
01:
Between Friends. Sort of.
April 2005
28:
Speak for Themselves, They Do
27:
Experimental Update, For Those Who Care
26:
Knocking Opportunity Costs
25:
What Ails the Germans?
25:
Live The Stereotype!
24:
The Consolations of Pure Research
21:
The Globalization of Med-Chem
20:
Sneaking Out for an Interview
19:
Getting A Job
18:
The Price of Desperation
18:
A Smelly Riddle
14:
How Good Is Aricept, Anyway?
13:
Vaccines by the Dozen
13:
A Steeplechase of Dead Horses
13:
Do It Again
07:
An Update
05:
In Memoriam
03:
Don't Talk To Yourself So Much
March 2005
31:
Why Carbon Matters
30:
Lost Arts
30:
More on Question Four
28:
Targretin's Troubles
27:
Ten Questions
23:
Drug versus Stock
22:
Still Not All That Easy
21:
Springtime for Oncology
20:
Ancient Metals
17:
Symlin, At Last
16:
Think Twice
15:
Back For More
12:
New Address
10:
Progress Through Craziness
09:
Rewiring the Brain?
08:
The Latest from the Fume Hood
07:
The Next Science
06:
Just How Many Compounds Are We Talking About?
03:
Things I Won't Work With: Carbon Diselenide
02:
Oh, Dear
01:
Too Interesting For Us
February 2005
28:
Tysabri's Fall
27:
Law Number One
24:
Getting a Faster PhD?
23:
Exobiochemistry
22:
An Antiviral Example
21:
Can Med-Chem Help With Bird Flu?
20:
COX-2 Aftermath
18:
Waiting for the FDA
17:
Law and Disorder
16:
Dysfunctional Disclosure
16:
Glaxo v. Pfizer: Sales Force Stand-Down?
14:
Bigger and Greasier
13:
Pfizer's Prospects
10:
The Bones of the World
09:
How'd We End Up Here, Anyway?
08:
Maybe They Should Fire Them All?
07:
One Problem Solved, Anyway
06:
A Technical Question
03:
Elbow Room
02:
Up There, and Down Here
01:
Merck Takes Another One
January 2005
31:
Does Your Labmate Have the Hands?
30:
Welcome to the World, I Hope
27:
Hope in a Drum
26:
Glassware Geek
25:
The Novartis Way
24:
What We Are Pleased to Call State of the Art
23:
A Trial Too Far
21:
And Now A Word. . .
20:
Through the Looking Plastic
19:
Bonfire of the Wonder Drugs
18:
Model Systems, From Inside and Out
17:
Don't Become A Scientist?
16:
More on Titan
14:
How Often Do We Land on Another World?
13:
Samuel Johnson Was Right
12:
Our Friend the Nitrogen Atom
11:
Right In Front of You
10:
The Example of Claritin
10:
Success Has A Thousand Fathers
06:
More Fun With DNA
05:
Like Moving Furniture Across a Tightrope
04:
Tadpoles to the Rescue?
03:
. . .Nor Am I Out of It
02:
Finishing, And Starting
December 2004
29:
Schedule Update
27:
Back Under the Sheets For Me
23:
Holiday Blogging
21:
Optioning the Drug Portfolio
21:
No Drug Is An Island
19:
Boarding Up the Windows
17:
The FDA Weighs In
17:
Black Friday: One Damn Thing After Another
17:
The Other COX-2 Shoe Drops
16:
Lab of the Future!
15:
Die-oxin?
14:
The Coming Oncology
13:
Fixing the Drug Industry?
12:
Stocking Stuffers, of a Sort
10:
An Economist Who Gets It
09:
Housecleaning
08:
Follow Which Money Where?
08:
An Experiment in Progress?
07:
Check, Please
07:
Alex Tabarrok on Me-Too Drugs
06:
Tarceva Targets
05:
Beg to Differ
02:
Blurry Copies
01:
Strangers on a Train
November 2004
30:
More on Woodward
29:
Archaeologists Announce Dirty Laundry Discovery
28:
Some Perspective
23:
Chemistry Geekery
23:
I Don't See How This Qualifies As Bliss
21:
Safe, And Other Four-Letter Words
18:
Nine Things I'm Having Trouble Imagining
17:
RNAi: The Awkward Age
16:
Things I Won't Work With: Ozonides
15:
Keep It To Yourself
14:
I'll Have the Lot
11:
Alexander Would Have Understood
10:
Cui Bono?
09:
Gumming Up the Amyloid Works
08:
Merck's State of Mind
07:
Take it Off!
05:
A Visit To Academia
03:
Don't Ask; Just Trade
02:
Let's See What the Sharks Think of These Steaks!
01:
Now With The Great Taste of Fish
October 2004
31:
Well, Sonny, That's Not How We Did It
30:
Special Off-Topic Weekend Irrelevancy
29:
Different or Not? You Tell Me.
27:
Pharma Flock Begins Migration
26:
It's All Local, All Right
25:
Actually, It's Everything Else That's Off-Topic
24:
A Spin of the Wheel
22:
Hey, I Could Patent That. . .
20:
Ping! Ping! Ping!
19:
Cox-2 Confusion
19:
Epidemic of Good Sense Spreading, Scientists Say
17:
Preach It, Brother
14:
Could I Have a Side Order of Risk With That?
14:
Circular Mistakes
12:
A Day in the Life: Dichloromethane and Peanut Butter
11:
Public Utility, You Say?
11:
Prices and Innovation
07:
How Bad Are the Cox-2 Inhibitors, Anyway?
06:
We Have Ways of Keeping You Safe
05:
Proteins to the Rescue?
05:
DNA to Drug?
03:
More on Merck
02:
Comment Problems
September 2004
30:
A Day With All the Bark Left On It
29:
Peter Rost, Oddity
28:
Kicking the Dinosaur's Tail - Again
28:
Rank and Yank?
23:
Measure for Mismeasure
22:
Rational Drug Design
20:
Two Days Off (From This, Anyway)
20:
Drug Development: The Current Odds
19:
No Coming Attractions Here
16:
The NIH in the Clinic
14:
One More On Basic Research and the Clinic
13:
A Real-World Can O' Worms
12:
How Much Basic Research?
09:
How It Really Works
08:
Unburied
07:
Angell's Book
02:
The Last Word (For A While) On Me-Too Drugs
01:
Around and About
August 2004
31:
Me Too, Part Two
31:
Clinical Trials And What to Do With Them
29:
. . .It's a Wonder I Can Think At All
26:
Things I Won't Work With: Polyazides
25:
Will the Uncommon Work for the Common Good?
24:
Living by the IP Sword
24:
I'll Have the Price They're Having
19:
Empty Shelves
18:
Resistance to Resistance
17:
Kinases and Their Komplications
16:
Clay Lies Still, But Blood's A Rover
15:
FullCell 1.0?
12:
A Week in the Life
10:
Memorial
10:
Solid Citizens
09:
Fast, Cheap, and Sometimes Even Good
05:
The State of the State of the Art
04:
Things I Won't Work With: A Nasty Condensed Gas
03:
Silent Mutations and Noisy Ones
02:
Research, The Right Way
01:
Furry Judges, With Tails
July 2004
30:
John Kerry on Drug Prices
29:
Down in the Salt Mine
28:
A Question For the Audience
28:
How Long Can This Go On?
26:
How Not to Do It: Sulfenyl Chlorides
25:
Costs and Benefits, Risks and Rewards
22:
Another Shot Across the Bow
20:
Worries about Rimonabant?
19:
Bungee Jumping with PPAR Drugs
18:
Back for More
08:
How Do You Know When to Stop?
06:
Lighting Out for the Frontier
04:
Happy Fourth of July
02:
The Two Ends of the Stick
01:
So What's Wrong With A Little Money Changing Hands?
June 2004
28:
No Defense
27:
Loose Lips
24:
Summer Hours
23:
It'll Cost You
21:
Primum Non Nocere, Eh?
21:
Le Dernier Cri
17:
You'd Think It Was An Election Year or Something
16:
The Dull Edge of Nanotech
15:
The Journals Fight Back
14:
Wipe Down
13:
Dumpster Diving for Data?
11:
The Agents Report Back
09:
Your One-Stop Clinical Data Superstore?
08:
Cue the Music
07:
Vox Populi
06:
As Goes ASCO. . .
03:
Doublets, Triplets, Whateverlets
02:
This Isn't the Kind of Office Action You're Thinking Of
02:
Industry vs. Academia: The Mental Aspect
May 2004
31:
How Not to Do It: Sodium
26:
The Latest From the Fishing Hole
25:
Down the Hatch
24:
What Ails Us
23:
Catalyst Catfishing
20:
A Capacious Rat-Hole Indeed
19:
All the Myriad Ways
19:
The Dose Makes the Poison
17:
Next on the Food Channel. . .
16:
Owning the Road
14:
The Last Word on Taste
12:
Beyond the Teeth, Beyond the Pale
11:
By Any Other Name
10:
Why Own the Car, When You Can Own the Road?
09:
Meetings and Their Discontents
06:
A Fire, And Its Flames
05:
Price Hydraulics
04:
Deferred Gratification Is Better Than None At All
03:
At My Desk, Playing 500-Card Stud
02:
Odd Elements in Drugs: Silicon
April 2004
29:
Yahoots
29:
An Era Begins
28:
Foaming Up Over the Edge
27:
Bulking Up
26:
Thou Hast It Now. . .
25:
How Not to Do It - Hydrogen Balloons
23:
Categories
22:
The Vapor Trail I Referred To
21:
Mutter, Mutter, Mutter
20:
Stuart Schreiber on Stuart Schreiber
19:
Odd Elements in Drugs
18:
The March of Folly Leader Board
16:
Welcome Back!
15:
The March of Folly
14:
Reality's Revenge
13:
It's a Bacterial Planet, You Know
06:
Osmium Tetroxide, Of All Things
05:
Oblivious to One Skilled in the Art
04:
Obvious to One Skilled in the Art
01:
Differences Between Academia and Industry, Pt. 2
March 2004
31:
No Better Than the Rest of Them
29:
Play It Again
28:
Thing I Won't Work WIth (2): Nickel Carbonyl
25:
A Birthday Worth Noting
25:
Tasty New Recipes for the Root of All Evil
23:
Getting the Word Out, For Once
22:
Quis custodiet ipsos custodes?
21:
The Root of All Results?
18:
Differences Between Industry and Academia, Pt. 1
17:
Our Cheerful Buddy, The Cell Membrane
15:
Pravachol vs. Lipitor Update
15:
The Universe, Which Others Call the Library. . .
14:
Mismatched Socks
11:
Ignorance Was Bliss
10:
A Mechanism for Thimerosal
09:
Nuclear Fusion, Wordsworth, German Cooking. The Usual.
07:
They Will Do Such Things. . .
04:
Welding the Steering Wheel
03:
Things I Won't Touch (1)
02:
Catching Up
February 2004
29:
More From the Me-Too Front
26:
Putting A Price on Proving It
25:
Ezetimibe, The Press, and More
24:
The Beginning? It's Right Past the End. . .
23:
One Of Us Is Hallucinating
22:
Reimportation's Just the Beginning
19:
One Of Us Is Hallucinating
19:
All Fixed Up
18:
How Drugs Die
16:
The Old Days, Some Older Than Others
15:
Drug Prices and Costs - From the Mail
15:
Easterbrook Post Updated
12:
More on Prices, High and Otherwise
12:
The Cold Equations
11:
The Contact Sport of Cost Accounting
09:
I will do such things - What they are yet I know not. . .
08:
Darn Those R&D Costs, Anyway
05:
Sic Transit Gloria Mundi
04:
Our Friend, the Carbon-Aluminum Bond
03:
Ricin Redux
02:
How to Be an Inventor
01:
Ricin Redux
01:
Deal Me In
January 2004
29:
From Each According To Their Creativity, To Each According To Their Difficulty?
28:
The Best Bad News He Ever Had
28:
Not in My European Back Yard
26:
Allons Pharmas de la Patrie!
25:
A Little Ambiguity Would Be Welcome Right About Now
22:
Dr. Lowe? I Have Your Hypothesis on Line Two
21:
. . .Your Huddled Pharmas Yearning to Breath Free
20:
Weinberg's "Golden Lessons"
19:
There'd Better Not Be an Argon Receptor
18:
All Bets Are Now Officially Off
15:
And Now for Something Completely Different
14:
The Pricing Weapon
13:
Here and There
12:
If This Doesn't Work, There's Only Reality To Fall Back On
11:
A New Cancer Target - Maybe
08:
A Request From Biology
07:
Good Sense Wins a Round
07:
Secretin
December 2003
07:
Good News, Backing Slowly Through the Door?
November 2003
28:
Waiting for the Metaphorical Phone to Ring
August 2003
03:
Per Fits and Starts, Ad Astra
January 2003
12:
Easy Parts and Hard Parts
09:
Back in the Stacks
08:
More Ricin
08:
The Library of Babel
07:
Ricin
06:
And Another Thing. . .
06:
Compare and Contrast
05:
Ratio Rationalizations
02:
The Rate of Autism
December 2002
30:
Back on the Air
22:
Clearance Sale
22:
Thimerosal - A Chemical Point
22:
Thimerosal - a Chemical Point
22:
Clearance Sale
20:
Trials of Trials
18:
Hypertension and Marketing
17:
Looking Back, Looking Forward
16:
Attitude
12:
A Rough Business
11:
A Quick One While He's Away
10:
Don't Wait - Patent Today!
09:
Proteinocentrism
09:
Sweet Maybe, But Trouble, Too
05:
A Quick Tour Through the Mudhole
05:
More on Autism (And Mercury)
05:
More on Autism and Mercury
05:
A Quick Tour Through the Mudhole
04:
Neurotoxins
04:
Neurotoxins
03:
Doing Justice to Thimerosal, And the Story
03:
Doing Justice to Thimerosal, and the Story
02:
Europe, Again
01:
Place Your Bets
November 2002
26:
Unequivocal Good News
25:
A Chemical Wish List
24:
A New Form of Hype, uh, Life?
21:
The Future and Its Friends
20:
What I, um, Meant to, um, Say
19:
Ah, Marketing
18:
Multitasking
17:
New! Improved! Now With Stickier Lumps!
14:
Statins and Multiple Sclerosis
14:
Left and Right, Revisited
12:
Y'all Are Going to Think I'm Nuts, But. . .
11:
Thalidomide in the Mirror
10:
Mismeasure for Mismeasure
07:
Measure for Measure
04:
Generic Prilosec - the Sequel
04:
The Good Old Days of Really Bad Teeth, Revisited
04:
It'll Be a While
04:
Pneumonia, of All Things
03:
Cholesterol Lowering, One Way or Another
October 2002
31:
And While We're On the Subject - Mercury?
31:
More Faces in Even More Clouds
30:
What Sort of Number Did You Have in Mind?
29:
Et in Arcadia Ego
28:
A Mystery Gas?
27:
O Brave New Market, That Has Such Medicines In It
24:
Of All Sad Words. . .
23:
The Latest Mudfight
21:
Structure-Inactivity Relationship Would Be More Like It
20:
Faces In the Clouds
17:
Not Even Funny
16:
Cloning's Growing Pains
15:
That Voodoo That We Do
14:
Gene Therapy Decisions
13:
Nobelity and Lesser Nobelity
11:
Alzheimer's Vaccine Refuses to Die
10:
Another Stuffed Shirt
09:
Nobel Time!
09:
The Bigger They Are
08:
Genetic Optimism
07:
Idle Hands
06:
Bad News at a Bad Hour of the Night
03:
Am I Blue?
02:
Voluntary. . .For Now
01:
Silver Tongues, Golden Hands?
01:
Overpatenting?
September 2002
30:
Where Credit's Due
29:
A Rake's Progress
26:
On the Money
25:
Different Opinions About A Difference That Makes No Difference
24:
The Wall Street Journal versus the FDA
22:
Sleeping Dragons
19:
More Fun With Patent Expirations
18:
As Others See Us
15:
Chemical Warfare, Part Five: The Real World
14:
Chemical Warfare, Part Four: More On Nerve Agents and Their Chemistry
13:
Chemical Warfare, Part Three: How Nerve Agents Work
12:
Chemical Warfare, Part Two: Lethal Agents (Other Than Nerve Gas)
12:
Chemical Warfare, Part One: Introduction
09:
Caveat Lector
08:
Merck and Its Competition
05:
You Don't Hear "Eureka" That Often
03:
The Patent Expiration Fun Continues
02:
A Last-Ditch Effort - Or Is It?
August 2002
29:
How Not to Do It: Solvent Stills
28:
Consequences of Aneuploidy
27:
Aneuploidy, or What're A Few Chromosomes, More or Less?
26:
Muddying the Water For Fun and Profit
25:
Back For Some More
20:
HER-1 And HER-2, Too
19:
They All Get Real at Some Point
18:
And I Still Have Some of Those Shirts
16:
Here It Goes
16:
Nature Stood Me Up
15:
Great Moments in Legal Reasoning
14:
Our Friend the Phosphate Group, Redux
13:
Our Friend the Phosphate Group
11:
Life of the Party
08:
Better Them Than Me
04:
Close to the Vest
04:
Close To the Vest
01:
Breathing and Aging
July 2002
30:
The Ames Test and the Real World
29:
The Ames Test
28:
Our Buddies at the FDA
25:
What to Do When the Rats Die on You
24:
Experimental Update
24:
And Always Keep Ahold of Nurse, For Fear of Finding Something Worse
23:
Rats, For Fear of Worse
22:
More on Drug Prices
21:
You'll Only Get Answers
19:
The Dismal Science of Drug Prices
18:
Talk, Cheap and Otherwise
17:
A Twisty Road
16:
Marketing Ueber Alles
16:
By Any Other Name
15:
The Apatosaurus. The Spruce Goose. The Pyramids
15:
The Irish Elk. The Mongol Empire. And Other Things That Got Too Big to Work Well.
12:
More Pfizer Explosion Details
11:
New! Viruses So Potent, You'd Swear They Were Homemade!
10:
Fighting City Hall
09:
Maybe They Can Formulate It in Madelaines
02:
Now, Where Was I?
June 2002
26:
A Race to the Bottom
25:
Blowups Happen
24:
Another Shot
23:
Stupidity, But Not the Dangerous Kind
18:
Save Your Tears
16:
A Strange Compound, In Strange Places
13:
The Company You Keep
11:
And All For a Little Money
06:
Adam Smith Goes Pharmaceutical
04:
A Clean Lab is A Happy Lab
03:
When Natural Selection's Through With You - Part II
03:
It's Not Pretty, But It Works
May 2002
31:
In Case Anyone's Wondering
30:
Innovation and Its Discontents
28:
Back to Whatever It Is I Do
23:
A Few Words
22:
Did He Say What They Thought He Said?
22:
Now Is the Peptide of Our Discontent
21:
Hype and Glory
20:
Hands Off
19:
Not As Bad As It Looks
15:
Eliminate the Middleman
14:
After Natural Selection's Through With You
12:
Back for More
06:
Meanwhile, Back at the Chocolate Factory
06:
Claritin and Clarinex
06:
So What's A Worthwhile Problem, Anyway?
03:
The Nuts and Bolts of a New Idea
02:
Measure Twice, Cut Once
02:
Anything Worth Doing. . .
April 2002
22:
Fun While It Lasted
19:
Colors May Fade
15:
A Treadmill Pill?
12:
A Less-Than-Subtle Plan
09:
And Another Thing
08:
F. Scott Fitzgerald Had Something to Say About This
07:
Get Your Miracle Elixir
02:
Nothing Like It in the World
01:
Enzymes, Right and Wrong
March 2002
28:
Not Like Law School
28:
Cruel to Be Kind
24:
What's a Project Manager to Do?
22:
More Colors and Smells
20:
If It Were Easy. . .
19:
Mirror Stars
10:
Separation Anxiety
February 2002
27:
More Imclone, More Food for Thought
27:
Who Dares, Wins?
26:
A Certain Tension in the Air
26:
New Drugs for HIV
25:
All the Not-So-Myriad Ways
24:
Toxicolottery
22:
Cartesian Aging
20:
Giordano Bruno
18:
A Couple of Days Off
14:
Modeling the Brain?
06:
Imclone in Progress
05:
Why Total Synthesis?
03:
Climbing Mountains
01:
Medicine Man
|
|
Warning: main(/home/corante/public_html/pipeline/includes/footer.html) [function.main]: failed to open stream: No such file or directory in /home/corante/public_html/pipeline/archives/date_index.php on line 15363
Warning: main(/home/corante/public_html/pipeline/includes/footer.html) [function.main]: failed to open stream: No such file or directory in /home/corante/public_html/pipeline/archives/date_index.php on line 15363
Warning: main() [function.include]: Failed opening '/home/corante/public_html/pipeline/includes/footer.html' for inclusion (include_path='.:/usr/lib/php:/usr/local/lib/php') in /home/corante/public_html/pipeline/archives/date_index.php on line 15363
| |
